

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199672148 B2**
(10) Patent No. **708148**

(54) Title
Tetrahydroquinolines as NMDA antagonists

(51)⁶ International Patent Classification(s)
C07D 215/48 A61K 031/47

(21) Application No: **199672148** (22) Application Date: **1996 .09 .26**

(87) WIPO No: **WO97/12870**

(30) Priority Data

(31) Number	(32) Date	(33) Country
9519893	1995 .09 .29	GB
9617306	1996 .08 .17	GB

(43) Publication Date : **1997 .04 .28**

(43) Publication Journal Date : **1997 .06 .19**

(44) Accepted Journal Date : **1999 .07 .29**

(71) Applicant(s)
Glaxo Wellcome S.p.A.

(72) Inventor(s)
Romano Di Fabio; Simone Giacobbe; Barbara Bertani; Fabrizio Micheli

(74) Agent/Attorney
DAVIES COLLISON CAVE,1 Little Collins Street,MELBOURNE VIC 3000

OPI DATE 28/04/97 APPLN. ID 72148/96
AOJP DATE 19/06/97 PCT NUMBER PCT/EP96/04206



AU9672148

(51) International Patent Classification ^o :
C07D 215/48, A61K 31/47

A1

(11) International Publication Number: WO 97/12870

(43) International Publication Date: 10 April 1997 (10.04.97)

(21) International Application Number: PCT/EP96/04206

(22) International Filing Date: 26 September 1996 (26.09.96)

(30) Priority Data:

9519893.3 29 September 1995 (29.09.95) GB
9617306.7 17 August 1996 (17.08.96) GB

(71) Applicant (for all designated States except US): GLAXO
WELLCOME S.P.A. [IT/IT]; Via Alessandro Fleming, 2,
I-37100 Verona (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): Di FABIO, Romano
[IT/IT]; (IT). GIACOBBE, Simone [IT/IT]; (IT).
BERTANI, Barbara [IT/IT]; (IT). MICHELI, Fabrizio
[IT/IT]; Glaxo Wellcome S.p.A., Via Alessandro Fleming,
2, I-37100 Verona (IT).

(74) Agent: FILLER, Wendy, Anne; Glaxo Wellcome plc, Glaxo
Wellcome House, Berkeley Avenue, Greenford, Middlesex
UB6 0NN (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT,
LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG,
US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ,
CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.

(54) Title: TETRAHYDROQUINOLINES AS NMDA ANTAGONISTS

(57) Abstract

Compounds of formula
(I) or a salt, or metabolically
labile ester thereof, processes
for the preparation thereof
and their use as antagonists of
excitatory amino acids.




TETRAHYDROQUINOLINES AS NMDA ANTAGONISTS

This invention relates to 1,2,3,4 tetrahydroquinoline derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. In particular, it relates to 1,2,3,4 tetrahydroquinoline derivatives which are potent and specific antagonists of excitatory amino acids.

Carling et al, Bioorganic and Medicinal Chemistry Letters Vol 13 pp 65-70 1993 teaches 4-substituted-2-carboxy tetrahydroquinolines having good *in vitro* affinity for the glycine modulatory site of the NMDA receptor complex but at best only weak *in vivo* activity. More particularly it teaches that such derivatives substituted at the 4 position by the group $\text{CH}_2\text{CO}_2\text{H}$ or CH_2CONHPh have little or no *in vivo* activity when administered systemically (ip).

We have found a novel group of 4 substituted 2-carboxy-tetrahydroquinoline derivatives which not only have a good *in vitro* affinity for the strychnine insensitive glycine binding site associated with the NMDA receptor complex but also good *in vivo* activity when administered intravenously (iv).

Thus the present invention provides a compound of formula (I)



or a salt, or metabolically labile ester thereof wherein R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino,

hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO_2R_2 or COR_2 wherein R_2 represents hydroxy, methoxy, amino, alkylamino or dialkylamino; m is zero or an integer 1 or 2;

5 R_1 represents hydrogen, alkyl, alkoxy, nitro, trifluoromethyl, halogen or $(\text{CH}_2)_n\text{R}_3$ wherein R_3 is hydroxy, COR_4 , NR_5R_6 , NHCOR_7 , or $\text{NHCONR}_8\text{R}_9$ group.

R_4 represents an alkoxy, amino or hydroxyl group;

R_5 and R_6 each independently represent hydrogen or alkyl group or

10 R_5 and R_6 together with the nitrogen atom to which they are attached represent a heterocyclic group;

R_7 represents a hydrogen atom or optionally substituted alkyl, alkoxy, aryl or heterocyclic group;

R_8 represents hydrogen or alkyl group;

15 R_9 represents hydrogen, optionally substituted alkyl, aryl, heterocyclic or cycloalkyl group;

n is zero or an integer from 1 to 4.

In compounds of formula (I) the exocyclic double bond is in the trans (E) configuration.

20

For use in medicine the salts of the compounds of formula (I) will be physiologically acceptable thereof. Other salts however may be useful in the preparation of the compounds of formula (I) or physiologically acceptable salts thereof. Therefore, unless otherwise stated, references to salts include

25

both physiologically acceptable salts and non-physiologically acceptable salts of compounds of formula (I).

Suitable physiologically acceptable salts of compounds of the invention include base addition salts and where appropriate acid addition salts.

30

Suitable physiologically acceptable base addition salts of compounds of formula (I) include alkali metal or alkaline metal salts such as sodium, potassium, calcium, and magnesium, and ammonium salts, formed with amino acids (e.g. lysine and arginine) and organic bases (e.g. procaine, phenylbenzylamine, ethanolamine, diethanolamine and N-methyl glucosamine).

35

The compounds of formula (I) and/or salts thereof may form solvates (e.g. hydrates) and the invention includes all such solvates.

5 Compounds of formula (I) and in particular the base addition salts thereof e.g. sodium salt have been found to have an advantageous profile of solubility in water.

10 The term alkyl as used herein as a group or part of a group refers to a straight or branched chain alkyl group containing from 1 to 4 carbon atom examples of such groups including methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, secondary butyl or tertiary butyl.

The term optionally substituted alkyl as used herein refers to an alkyl group as defined above and which is substituted by one or more hydroxy, carboxyl, and amino groups.

15 The term halogen refers to a fluorine, chlorine, bromine or iodine atom.

The term aryl, as used throughout the description and the claims, refers to an optionally substituted phenyl group or a 5 or 6 membered heteroaryl in which the 5-membered heteroaryl group contains 1 or 2 heteroatoms selected from oxygen sulphur or nitrogen and 6-membered heteroaryl group containing 1 or 2 nitrogen atoms.

20 Examples of suitable heteroaryl groups include furanyl, thiophenyl, imidazolyl, thiazolyl, oxazolyl, pyridinyl, and pyrimidinyl.

25 The term optionally substituted phenyl refers to a phenyl group substituted with up to 3 substituents selected from halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, amino, alkylamino, hydroxy, trifluoromethyl, carboxyl or methoxycarbonyl.

30 The term cycloalkyl refers to a C₃₋₇ cycloalkyl group which may optionally be substituted or 1 or 2 C₁₋₄ alkyl groups e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or 2-methylcyclohexyl.

35 The term optionally substituted heterocyclic group refers to 5-7 membered saturated heterocyclic groups containing one or two heteroatoms selected from oxygen, sulphur or nitrogen. Examples of suitable groups containing a single heteroatom include tetrahydropyranyl e.g. 4-tetrahydropyranyl, pyrrolidinyl e.g. 2 or 3 pyrrolidinyl, piperidinyl e.g. 4- or 3-piperidinyl and N-



substituted derivatives therefore (e.g. N-alkyl such as e.g. methyl or N-acyl such as N-alkanoyl e.g. acetyl or N-alkoxycarbonyl e.g. ethoxycarbonyl), piperidino or pyrrolidino. Examples of suitable groups containing 2 heteroatoms include morpholino, thiomorpholino or piperazino.

5

When R₅ and R₆ together with the nitrogen atom to which they are attached represent an heterocyclic group this is a saturated 5-7 membered ring optionally containing an additional heteroatom selected from oxygen, sulphur or nitrogen.

10

Examples of such groups include morpholino, 2,6 dimethylmorpholino, piperidino, pyrrolidino, piperazino or N-methylpiperazino.

15

The compounds of formula(I) possess at least one asymmetric carbon atom (namely the carbon atom occupying the 2 position of the 1, 2, 3, 4 tetrahydroquinoline ring system) and other asymmetric carbon atoms are possible in the groups R and R₁. It is to be understood that all enantiomers and diastereoisomers and mixtures thereof are encompassed within the scope of the present invention.

20

It will be appreciated that the compounds of formula (I) may be produced *in vivo* by metabolism of a suitable prodrug. Such prodrugs include for example physiologically acceptable metabolically labile esters of compounds of the general formula (I). These may be formed by esterification, for example of any of the carboxylic acid groups in the parent compound of general formula (I) with, where appropriate, prior protection of any other reactive groups present in the molecule, followed by deprotection if required. Examples of such metabolically labile esters include C₁₋₄alkyl esters e.g. methyl or ethyl esters, substituted or unsubstituted aminoalkyl esters (e.g. aminoethyl, 2-(N,N- diethylamino) ethyl, or 2-(4-morpholino)ethyl esters or acyloxyalkyl esters such as, acyloxymethyl or 1-acyloxyethyl e.g. pivaloyloxymethyl, 1-pivaloyloxyethyl, acetoxymethyl, 1-acetoxyethyl, 1-(1-methoxy-1-methyl)ethylcarbonyloxyethyl, 1-benzoyloxyethyl, isopropoxycarbonyloxymethyl, 1-isopropoxycarbonyloxyethyl, cyclohexylcarbonyloxymethyl, 1-

35

cyclohexylcarbonyloxyethyl ester, cyclohexyloxycarbonyloxymethyl, 1-cyclohexyloxycarbonyloxyethyl, 1-(4-tetrahydropyranyloxy)carbonyloxyethyl or 1-(4-tetrahydropyranyl)carbonyloxyethyl.

- 5 For compounds of formula (I) m is conveniently 1 or 2 and within these compounds those wherein R is at the 5 and/or 7 position are preferred.

The group R is conveniently a halogen atom, such as bromine or chlorine and preferably is a chlorine atom.

10

The substituent R_1 may be in the 2, 3 or 4 position in the phenyl ring. Conveniently R_1 is at the 3 or 4 position and is preferably at the 4 position. When R_1 is the group $(CH_2)_nR_3$ n is conveniently zero, 1 or 2.

- 15 Examples of suitable R_1 group include hydrogen, halogen e.g. chlorine, alkoxy e.g. methoxy, $(CH_2)_nCOR_4$ wherein R_4 is amino or hydroxyl, $(CH_2)_nNR_5R_6$ in which R_5 is hydrogen and R_6 is hydrogen or alkyl e.g. methyl, ethyl, or NR_5R_6 represents a saturated 6 membered ring containing oxygen e.g. morpholino, $(CH_2)_nNHCOR_7$ wherein R_7 is hydrogen, alkyl e.g. methyl, isopropyl, isobutyl, aryl group e.g. phenyl or pyridyl e.g. 3-pyridyl or
20 $(CH_2)_nNHCONHR_9$ wherein R_9 is hydrogen, phenyl (optionally substituted with methoxy), heterocyclic e.g. 4-tetrahydropyranyl or cycloalkyl e.g. cyclopropyl or cyclohexyl. Within these groups of compounds n is conveniently zero 1 or 2.

- 25 A preferred group of compounds of formula (I) are those wherein m is 2 and R which is at the 5 and 7 position is bromine or more particularly chlorine.
A further preferred group of compounds of formula (I) are those wherein R_1 is hydrogen, chlorine, $(CH_2)_nCOR_4$ wherein R_4 is hydroxyl or amino and n is zero, 1 or 2, e.g. carboxymethyl or carbamoylmethyl, $(CH_2)_nNR_5R_6$
30 wherein R_5 and R_6 are each hydrogen or NR_5R_6 represents a morpholino group and n is zero 1 or 2 e.g. amino or morpholinomethyl $(CH_2)_nNHCOR_7$ wherein R_7 is hydrogen or C_{1-4} alkyl e.g. methyl, isopropyl or isobutyl, n is zero 1 or 2 e.g. acetamido, acetamidomethyl, acetamidoethyl, formamidomethyl, isobutyrylamino, isobutyrylaminoethyl,

isobutyrylaminoethyl, 3-methylbutyrylaminoethyl, $(\text{CH}_2)_n\text{NHCONH}_2$
wherein n is zero, 1 or 2 e.g. ureidomethyl:

Specific preferred compounds of the invention include:-

- 5 (±) (E) 4-(4-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid,
- (±) (E) 5,7- Dichloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 7- Chloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-10 2-carboxylic acid,
- (±) (E) 5,7- Dibromo-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 4-(4-Amino-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- 15 (±) (E) 4-(3-Acetylamino-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 5,7- Dichloro- 4-(4-isobutyrylamino-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 5,7- Dichloro- 4-[4-(3-methyl-butrylamino)-20 phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid
- (±) (E) 5,7- Dichloro- 4-(3-chloro-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 5,7- Dichloro- 4-[4-(isobutyrylamino-methyl)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid
- 25 (±) (E) 5,7- Dichloro- 4-[4-(ureidomethyl)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 4-[4-(Acetylamino-methyl)-phenylcarbamoylmethylene]-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 5,7- Dichloro- 4-(4-formylaminomethyl-phenylcarbamoylmethylene)-30 1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- (±) (E) 5,7- Dichloro- 4-(4-morpholin-4-ylmethyl-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid
- (±) (E) 4-[4-(2-Acetylamino-ethyl)-phenylcarbamoylmethylene]-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

- (±) (E) 5,7- Dichloro- 4-[4-(2-isobutyrylamino-ethyl)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid
(±) (E) 4-(4-Carbamoylmethyl-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
- 5 (±) (E) 4-(4-Carboxymethyl-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,
and physiologically acceptable salts e.g. sodium salt or metabolically labile esters thereof.
- 10 The compounds of formula (I) and/or physiologically acceptable salts thereof are excitatory amino acid antagonists. More particularly they are potent antagonists at the strychnine insensitive glycine binding site associated with the NMDA receptor complex. As such they are potent antagonists of the NMDA receptor complex. These compounds are
- 15 therefore useful in the treatment or prevention of neurotoxic damage or neurodegenerative diseases. Thus the compounds are useful for the treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral vasospasm, hypoglycemia, anaesia, hypoxia, anoxia, perinatal asphyxia cardiac arrest.
- 20 The compounds are useful in the treatment of chronic neurodegenerative diseases such as; Huntingdon's disease, Alzheimer's senile dementia, amyotrophic lateral sclerosis, Glutaric Acidaemia type, multi-infarct dementia, status epilepticus, contusive injuries (e.g. spinal cord injury and head injury), viral infection induced neurodegeneration (e.g. AIDS,
- 25 encephalopathies), Down syndrome, epilepsy, schizophrenia, depression, anxiety, pain, neurogenic bladder, irritative bladder disturbances, drug dependency, including withdrawal symptoms from alcohol, cocaine, opiates, nicotine, benzodiazepine, and emesis.
- 30 The potent and selective action of the compound of the invention at the strychnine- insensitive glycine binding site present on the NMDA receptor complex may be readily determined using conventional test procedures. Thus the ability to bind at the strychnine insensitive glycine binding site was determined using the procedure of Kishimoto H et al. J Neurochem 1981, 37
- 35 1015-1024. The selectivity of the action of compounds of the invention for

the strychnine insensitive glycine site was confirmed in studies at other ionotropic known excitatory amino acid receptors. Thus compounds of the invention were found to show little or no affinity for the kainic acid (kainate) receptor, α -amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor or at the NMDA binding site.

Compounds of the invention have also been found to inhibit NMDA induced convulsions in mice using the procedure Chiamulera C et al. Psychopharmacology (1990) 102, 551-552.

The invention therefore provides for the use of a compound of formula (I) and/or physiologically acceptable salt or metabolically labile ester thereof for use in therapy and in particular use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

The invention also provides for the use of a compound of formula (I) and/or a physiologically acceptable salt or metabolically labile ester thereof for the manufacture of a medicament for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

According to a further aspect, the invention also provides for a method for antagonising the effects of excitatory amino acids upon the NMDA receptor complex, comprising administering to a patient in need thereof an antagonistic amount of a compound of formula (I) and/or a physiologically acceptable salt or metabolically labile ester thereof.

It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established diseases or symptoms.

It will further be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated, the route of administration and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician. In general however doses employed for adult human treatment will typically be

in the range of 2 to 800mg per day, dependent upon the route of administration.

Thus for parenteral administration a daily dose will typically be in the range 20-100mg, preferably 60-80mg per day. For oral administration a daily dose
5 will typically be within the range 200-800mg, e.g. 400-600mg per day.

The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.

10

While it is possible that, for use in therapy, a compound of the invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation.

15

The invention thus further provides a pharmaceutical formulation comprising a compound of formula (I) or a pharmaceutically acceptable salt or metabolically labile ester thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be
20 'acceptable' in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

25

The compositions of the invention include those in a form especially formulated for oral, buccal, parenteral, inhalation or insufflation, implant, or rectal administration. Parenteral administration is preferred.

30

Tablets and capsules for oral administration may contain conventional excipients such as binding agents, for example, syrup, accacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone; fillers, for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol; lubricants, for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica; disintegrants, for example, potato starch or sodium starch glycollate, or wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in
35 the art. Oral liquid preparations may be in the form of, for example,

aqueous or oily suspensions, solutions emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats; emulsifying agents, for example, lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; solubilizers such as surfactants for example polysorbates or other agents such as cyclodextrins; and preservatives, for example, methyl or propyl p- hydroxybenzoates or ascorbic acid. The compositions may also be formulated as suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The composition according to the invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may be presented in unit dose form in ampoules, or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

For administration by inhalation the compounds according to the invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs, with the use of a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable propellants, such as dichlorodifluoromethane, trichlorofluoromethane, dichloro-tetrafluoroethane, carbon dioxide or other suitable gases, or from a nebuliser. In the case of a

pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount.

Alternatively, for administration by inhalation or insufflation, the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable carrier such as lactose or starch. The powder composition may be presented in unit dosage form in, for example, capsules or cartridges of e.g. gelatin, or blister packs from which the powder may be administered with the aid of an inhaler or insufflator.


The composition according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions according to the invention may contain between 0.1 - 99% of the active ingredient, conveniently from 30- 95% for tablets and capsules and 3-50% for liquid preparations.

Compounds of general formula (I) and salts thereof may be prepared by the general methods outlined hereinafter. In the following description, the groups R, m, R₁ are as defined for the compounds of formula (I) unless otherwise stated.

Compounds of formula (I) may be prepared by the cyclisation of a compound of formula (II) in which R₁₀ is a carboxylic protecting group, R₁₁ represents a bromine or iodine atom, R₁₂ represents hydrogen or a nitrogen protecting group and R₁ has the meanings defined in formula(I) or a protected derivative thereof,

12



(II)

5 followed where necessary or desired by removal of one or more protecting groups.

In one embodiment of this process the reaction may be carried out using a catalytic amount of a Palladium (O) complex such as tetrakis(triphenylphosphine)palladium and a suitable organic base such as trialkylamine e.g. triethylamine or inorganic base, e.g. potassium carbonate.
 10 The reaction is conveniently carried out in an aprotic solvent such as acetonitrile or dimethylformamide at a temperature with the range of 60°C to 150°C followed, where necessary or desired, by subsequent removal of the carboxyl protecting group R₁₀ and any protecting group R₁₂.


15 In a further embodiment of the process the reaction is carried out using a catalytic amount of a Pd(II) salt such as: palladium acetate, in the presence of a suitable organic base such as trialkyl amine e.g. triethylamine and of a triarylphosphine such as triphenylphosphine.

20 The reaction is carried out in an aprotic solvent such as acetonitrile or dimethylformamide and preferably with heating, where necessary or desired, by subsequent removal of the carboxyl protecting group R₁₀ and any protecting group R₁₂.


25 Suitable carboxyl protecting groups R₁₀ for use in this reaction include alkyl, trichloroalkyl, trialkylsilylalkyl, or arylmethyl groups such as benzyl, nitrobenzyl or trityl.

When R_{12} is nitrogen protecting examples of suitable groups include alkoxycarbonyl e.g. t-butoxycarbonyl, arylsulphonyl e.g. phenylsulphonyl or 2-trimethylsilylethoxymethyl.

- 5 In a further process of the invention compounds of formula(I), may be prepared by reaction of an activated derivative of the carboxylic acid (III) in which R_{10} is a carboxyl protecting group and R_{12} is hydrogen or a nitrogen protecting group as defined in formula (II)



with the amine(IV)



wherein R_1 has the meaning defined in formula(I) or a protected derivative thereof, followed where necessary by subsequent removal of the carboxyl protecting group R_{10} and any nitrogen protecting group R_{12} .

- 20 Suitable activated derivatives of the carboxyl group include the corresponding acyl halide, mixed anhydride, activated ester such as a thioester or the derivative formed between the carboxylic acid group and a coupling agent such as that used in peptide chemistry, for example carbonyl diimidazole or a diimide such as dicyclohexylcarbodiimide.

- 25 The reaction is preferably carried out in an aprotic solvent such as a hydrocarbon, a halohydrocarbon, such as dichloromethane or an ether such as tetrahydrofuran.


Suitable carboxyl protecting groups R_{10} for use in this reaction include alkyl, trichloroalkyl, trialkylsilylalkyl, or arylmethyl groups such as benzyl, nitrobenzyl or trityl.

- 5 When R_{12} is nitrogen protecting examples of suitable groups include alkoxycarbonyl e.g. t-butoxycarbonyl, arylsulphonyl e.g. phenylsulphonyl or 2-trimethylsilylethoxymethyl

The activated derivatives of the carboxylic acid (III) may be prepared by conventional means. A particularly suitable activated derivative for use in
10 this reaction is thioester such as that derived from pyridine-2-thiol. These esters may conveniently be prepared by treating the carboxylic acid (III) with 2,2'-dithiopyridine and triphenylphosphine in a suitable aprotic solvent such as an ether e.g. tetrahydrofuran, a halohydrocarbon e.g. dichloromethane, an amide e.g. N,N-dimethylformamide or acetonitrile.

- 15 Compounds of formula (I) wherein R_1 is $(CH_2)_nNHCOR_7$ in which R_7 has the meaning defined in formula(I) may be also prepared by reaction of the amine (V) wherein (R),m, R_{12} and R_{10} have the meanings defined in formula(I)

20



- 25 with an activated derivative of the acid R_7CO_2H wherein R_7 has the meaning defined in formula(I) or is protected derivatives thereof, followed where appropriate by removal of any protecting groups.

Suitable activated derivatives of the acid R_7CO_2H include the corresponding acyl halides e.g. acyl chlorides. The reaction is conveniently carried out in an aprotic solvent such as ether e.g. tetrahydrofuran and in the presence of a base such as tertiary amine e.g. triethylamine.

5 Compounds of formula(I) wherein R_1 is $(CH_2)_nNHCONR_8R_9$ group in which R_8 and R_9 have the meanings defined in formula(I) may be also prepared by reaction of the amine derivative of formula(V) with an isocyanate of formula(VI) wherein R_8 and R_9 have the meaning defined in
10 formula(I) or are protected derivatives thereof or with the compound(VII) wherein R_8 and R_9 have the meanings defined in formula(I) or are protected derivatives thereof and R_{13} is optionally substituted phenoxy, halogen or imidazole group followed where necessary or desired by removal of any protecting group.



The reaction with the compound(VI) is conveniently carried out in a solvent such as tetrahydrofuran or aqueous tetrahydrofuran, a halohydrocarbon(e.g.
20 dichloromethane) or acetonitrile optionally in the presence of a base such as triethylamine, and at a temperature with the range of 0-80°C.

The reaction with the compound(VII) is preferably carried out in a solvent such as halohydrocarbon(e.g. dichloromethane) or an ether(e.g.
25 tetrahydrofuran) or an amide (e.g. N,N-dimethylformamide) at a temperature with the range of room temperature to the reflux temperature of the solvent and optionally in the presence of a base such as tertiary amine e.g. triethylamine. When the reaction is carried out using a compound of formula(VII) wherein R_{13} is halogen the reaction is conveniently carried out
30 at a temperature with the range 0-60°C.


Suitable carboxyl protecting groups R_{10} for use in this reaction include alkyl, trichloroalkyl, trialkylsilylalkyl, or arylmethyl groups such as benzyl, nitrobenzyl or trityl.
35

When R_{12} is nitrogen protecting examples of suitable groups include alkoxy carbonyl e.g. t-butoxycarbonyl, arylsulphonyl e.g. phenylsulphonyl or 2-trimethylsilylethoxymethyl

5


Compounds of formula (II) may be prepared from compound of formula (VIII) in which R_{10} is a carboxyl protecting group and R_{12} is hydrogen or a nitrogen protecting group as defined in formula (II) and R_{11} represents a bromine or iodine atom

10



by reaction with an appropriate phosphorus reagent capable of converting the group CHO into the group :


15



followed, where necessary or desired, by removal of the carboxyl protecting group R_{10} and nitrogen protecting group R_{12}

20

In one embodiment of this process the reaction may be carried out using a phosphorus ylide of formula (IX)




25

wherein R_{14} is an alkyl or phenyl group and R_1 has the meanings defined in formula (I) or a protected derivative thereof.

The reaction is carried out in an aprotic solvent such as acetonitrile or dimethylformamide at a temperature ranging from -10°C to the reflux temperature of the solvent.


- 5 Compounds of formula (VIII) may be prepared by ozonization of the allyl compound of formula (X) in which R_{10} is a carboxyl protecting group, R_{12} is hydrogen or a nitrogen protecting group as defined above and R_{11} represents a bromine or iodine atom.

10




- 15 The reaction may be effected by passing a stream of ozone into a solution of compound of formula (X) in the presence of dimethyl sulphide or triphenylphosphine in a suitable solvent such as halohydrocarbon e.g. dichloromethane at low temperature e.g. -78°C .

- 20 Compounds of formula (X) wherein R_{12} is hydrogen atom and R_{10} is carboxyl protecting group as defined above may be prepared by reaction of the amine (XI) wherein R_{11} represents a bromine or iodine atom with the aldehyde (XII) in which R_{10} is carboxyl protecting group



25




followed by addition of allyltributyltin in the presence of Lewis acid such as titanium(IV) chloride or boron trifluoride etherate. The reaction conveniently

takes place in a solvent such as hydrocarbon e.g. toluene or halogenated hydrocarbon e.g. dichloromethane at a temperature ranging from -78°C to room temperature.

- 5 Compounds of formula (X) in which R_{12} is nitrogen protecting group and R_{10} is carboxyl protecting group as defined above may be prepared from the compound of formula (X) wherein R_{12} represents hydrogen atom using conventional procedure for preparing such protected nitrogen atom.
- 10 Compounds of formula (III) may be prepared by the cyclisation of a compound of formula (XIII) in which R_{10} is a carboxylic protecting group, R_{11} represents a bromine or iodine atom, R_{12} represents hydrogen or a nitrogen protecting group as defined above, and R_{15} represents a suitable carboxyl protecting group such as t butyl group

15



(XIII)

- using similar reaction conditions for those described above for the
- 20 cyclisation of compounds of formula (II), followed by removal of the carboxyl protecting group R_{15} and where necessary or desired by removal of the nitrogen protecting group R_{12}
- Compounds of formula (XIII) may be prepared from compound of formula (VIII) and a phosphorus ylide $(R_{14})_3\text{P}=\text{CHCO}_2R_{15}$ in which R_{14}
- 25 has the meaning defined in formula (IX) and R_{15} is defined above, using similar reaction condition for those described above for the reaction of (VIII) with compound of formula (IX).

Compounds of formula (V) may be prepared by any of the processes described by the general procedures described above for preparing compounds of formula (I) using the appropriate intermediates (II), (IV), (IX)

- 5 Compounds of formula (IV), (VI), (VII) (IX), (XI) and (XII) are either known compounds or may be prepared by analogous methods to those used for known compounds.

10 In any of the above reactions the carboxyl protecting group may be removed by conventional procedures known for removing such groups. Thus compounds where R₁₀ is a benzyl group, this may be removed by hydrolysis using an alkali metal hydroxide e.g. lithium hydroxide or sodium hydroxide in a suitable solvent such as ethanol or isopropanol, water or mixtures thereof, followed, where desired or necessary, by that addition of a
15 suitable acid e.g. hydrochloric acid to give the corresponding free carboxylic acid.

In any of the above reactions the nitrogen protecting group may be removed by conventional procedures known for removing such groups, for example by acid or base hydrolysis. Thus when R₁₂ is alkoxycarbonyl e.g. t-butoxycarbonyl or phenylsulphonyl it may be removed by alkaline hydrolysis
20 using for example lithium hydroxide in a suitable solvent such as tetrahydrofuran or an alkanol e.g. isopropanol. Alternatively the alkoxycarbonyl group may be removed by acid hydrolysis. When R₁₅ is t-butyl group this may be removed by hydrolysis using organic acids eg formic acid.
25

Physiologically acceptable salts of compounds of formula (I) may be prepared by treating the corresponding acid with an appropriate base in a suitable solvent. For example alkali and alkaline metal salts may be
30 prepared from an alkali or alkaline metal hydroxide, or the corresponding carbonate or bicarbonate thereof. Alternatively alkali or alkaline metal salts may be prepared by direct hydrolysis of carboxyl protected derivatives of compounds of formula (I) with the appropriate alkali or alkaline metal hydroxide.

35

Metabolically labile esters of compounds of formula (I) may be prepared by esterification of the carboxylic acid group or a salt thereof or by transesterification using conventional procedures. Thus, for example, acyloxyalkyl esters may be prepared by reacting the free carboxylic acid or a salt thereof with the appropriate acyloxyalkyl halide in a suitable solvent such as dimethylformamide. For the esterification of the free carboxyl group this reaction is preferably carried out in the presence of a quaternary ammonium halide such as tetrabutylammonium chloride or benzyltriethylammonium chloride.

Aminoalkyl esters may be prepared by transesterification of a corresponding alkyl ester e.g. methyl or ethyl ester by reaction with the corresponding aminoalkanol at an elevated temperature e.g. 50-150°.

In order that the invention may be more fully understood the following examples are given by way of illustration only.

In the Intermediates and Examples unless otherwise stated:

Melting points (m.p.) were determined on a Gallenkamp m.p. apparatus and are uncorrected. All temperatures refers to °C. Infrared spectra were measured on a FT-IR instrument. Proton Magnetic Resonance (¹H-NMR) spectra were recorded at 400 MHz, chemical shifts are reported in ppm downfield (δ) from Me₄Si, used as internal standard, and are assigned as singlets (s), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or multiplets (m). Column chromatography was carrier out over silica gel (Merck AG Darmstadt, Germany). The following abbreviations are used in text: EA = ethyl acetate, CH = cyclohexane, DCM = dichloromethane, THF = tetrahydrofuran, TFA = trifluoroacetic acid, TEA = triethylamine, PPA = polyphosphoric acid, DBU = 1,8-diazobicyclo [5,4,0]undec-7-ene, DMSO = dimethylsulphoxide, Tlc refers to thin layer chromatography on silica plates. Solution were dried over anhydrous sodium sulphate; r.t. (RT) refers to room temperature.

Intermediate 1

4-Chloro-1-iodo-2-nitrobenzene

To a suspension of 4-chloro-2-nitroaniline (5.18 g) in a 12N sulphuric acid solution (60 ml) cooled to 10 ° a solution of sodium nitrite (2.76 g) in sulphuric acid (20 ml) and polyphosphoric acid (40 ml) were sequentially added. The reaction mixture was stirred for 3 hrs at r.t., then poured into crushed ice and urea was added until gas evolution ceases. The resulting solution was treated with an aqueous solution (20 ml) of potassium iodide (7.47 g) and heated at 70° for 1 h. The mixture was diluted with brine and extracted with EA then the organic phase was washed with brine, dried and concentrated in vacuo. The residue was purified by flash column chromatography (CH / EA = 100 / 0 to 95 / 5 as eluant), obtaining the title compound as yellow solid (7.96 g). m.p. = 55-56 °C.

¹H-NMR (CDCl₃): 7.98 (1H, d); 7.80 (1H, d); 7.28 (1H, dd).
IR (neat): $\nu_{\max}$ (cm⁻¹) = 1535 (NO₂); 1354 (NO₂).

Intermediate 2**5-chloro-2-iodo-aniline**

To a solution of intermediate 1 (3.71 g) in 95% ethanol (25 ml) acetic acid (25 ml) and iron (2.98 g) were added. The reaction mixture was heated at 100° for 1 hr, then poured into brine, and sodium hydrogencarbonate powder was added until pH = 10. After extraction with EA, the organic phase was washed with brine, dried and evaporated, affording the title compound as yellow oil (3.60 g).

¹H-NMR (CDCl₃): 7.5 (1H, d); 6.7 (1H, d); 6.5 (1H, dd); 4.2 (2H, bs).
IR (neat): $\nu_{\max}$ (cm⁻¹) = 3468(NH₂); 3371 (NH₂); 1610 (C=C).

Intermediate 3**(+/-) 2-(5-chloro-2-iodo-phenylamino)-pent-4-enoic acid benzyl ester**

To a solution of intermediate 2 (1.05g) in dry toluene (15ml) benzylglyoxylate (750mg) and Na₂SO₄ (2g) were added. The mixture was

refluxed overnight. After filtration the resulting solution was concentrated under vacuum to a brown oil, which was then taken up with dichloromethane (30ml). After cooling to -78° , TiCl_4 (0.46ml) was slowly added with a syringe and stirring continued for 5 min. The solution was then allowed to warm to room temperature over 30min by removing the dry ice/acetone bath, then cooled again to -78° and tributylalyltin (2.6 ml) added. After 1 hour the reaction was stopped by pouring it into a saturated solution of NH_4Cl (100ml). The aqueous phase was extracted with EA (2X150ml) and the combined organic fractions washed with HCl (3N, 2x50ml) and brine (50ml) and dried. Final purification by column chromatography (CH/EA 95/15) gave the title compound (1.4g) as a colorless oil.

^1H NMR d (CDCl_3) 7.55 (d, 1H), 7.34 (m, 5H), 6.47 (dd, 1H), 6.42 (d, 1H), 5.73 (m, 1H), 5.19 (m, 4H), 4.82 (d, 1H), 4.17 (m, 1H), 2.65 (m, 2H).

15 **Intermediate 4**

(+/-) 2-(5-Chloro-2-iodo-phenylamino)-4-oxo-butyric acid benzyl ester

Intermediate 3 (1.43g) was dissolved in dry dichloromethane and the resulting solution cooled to -78° with a dry ice/acetone bath. Ozone was bubbled through it until a brick-red color appeared (approx 10min), then triphenylphosphine (0.92g) was added and the cooling bath removed. After the warm-up was complete the solution was concentrated to dryness on the rotary evaporator and finally purified by column chromatography (CH/EA 85/25) to give the title compound (0.86g) as a colorless oil.

^1H NMR: d (CDCl_3) 9.77 (t, 1H), 7.57 (d, 1H), 7.37 (m, 5H), 6.54 (d, 1H), 6.51 (dd, 1H), 5.20 (s, 2H), 4.99 (d, 1H), 4.52 (m, 1H), 3.07 (m, 2H).

IR: (CDCl_3) ν_{max} (cm^{-1}) 1730.

30 **Intermediate 5**

(+/-)(E)7-Chloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydroquinoline-2-carboxylic acid benzyl ester

To a solution of intermediate 4 (0.185g) in dry acetonitrile (10ml) and cooled to -10° phenylcarbamoylmethyl triphenylphosphonium bromide (0.241g) and

DBU (0.08ml) were added with stirring. A white precipitate immediately formed: after 1 hour it was isolated by filtration, washed with small amounts of cold acetonitrile and dried under vacuum to give the crude(+/-)(E)2-(5-Chloro-2-iodo-phenylamino)-5-phenylcarbamoyl-pent-4-enoic acid benzyl ester (0.156g) which was dissolved in dry acetonitrile (20ml) and the solution deoxygenated by bubbling through it dry N₂. To this solution, tetrakis(triphenylphosphine)palladium(0.032g) and triethylamine (0.08ml) were added and the reaction vessel sealed and heated to 80° for 2 hours. The brown mixture was then cooled, diluted with EA (100ml) and washed with a saturated solution of NH₄Cl (50ml). After drying with brine and with Na₂SO₄ the crude product was purified by column chromatography (CH/EA 4/1 to 3/1) to give the title compound (0.035g) as a white solid.

¹H NMR: d (CDCl₃) 10.03 (bs, 1H), 7.64 (m, 4H), 7.38 (d, 1H), 7.30 (m, 2H), 7.22 (m, 5H), 7.03 (m, 1H), 7.03 (m, 1H), 6.96 (bd, 1H), 6.78 (d, 1H), 6.61 (dd, 1H), 6.49 (s, 1H), 5.05 (m, 2H), 4.28 (m, 1H), 4.15 (dd, 1H), 3.02 (m, 1H).

IR: (nujol) $\nu_{\max}$ (cm⁻¹) 3385-3287, 1720-1645, 1599

Intermediate 6
4,6-Chloro-1-iodo-2-nitrobenzene

2-Nitro-4,6-dichloroaniline (5g) was dissolved in a 12N solution of H₂SO₄(20ml) and cooled at 0°. Then, a solution of NaNO₂ (2.15g) in H₂SO₄ (5ml) was carefully added followed by polyphosphoric acid (40ml). The reaction mixture was allowed to warm at room temperature and stirred for 3hrs. Then, the solution was poured into crushed ice and urea was added until gas evolution ceased. The resulting mixture was treated with an aqueous solution of potassium iodide (5.6g) and heated at 70° for 2hrs. The reaction mixture was diluted with a 10% solution of sodium hydroxide (40ml), extracted with ethyl acetate (3x40ml), washed with brine (3x25ml), dried and concentrated under vacuum. The title compound was obtained as a red oil (7.5g).

¹H-NMR (CDCl₃): 7.67 (1H, d); 7.54 (1H, d).

I.R.(nujol): 1454cm⁻¹, 1350cm⁻¹.

Intermediate 7

2-Iodo-3,5-dichloroaniline

5

To a solution of Intermediate 6 (4g) in 95% ethanol (35ml) glacial acetic acid (35ml) and iron (2.8g) was added. The reaction mixture was heated at 100° for 1 h then diluted with a saturated solution of sodium hydrogencarbonate and extracted with ethyl acetate (3X20ml). The organic layer was washed with brine (2x20ml), dried, evaporated under vacuum to give the title compound as brown solid (2.9g).

10

IR (nujol): $\nu_{\max}$ (cm⁻¹) = 3491(NH₂); 3103 (NH₂); 1614 (C=C).

Intermediate 8

15

(±) 2-(3,5-dichloro-2-iodo-phenylamino)-pent-4-enoic acid benzyl ester

To a solution of intermediate 7(1.5g) in dry toluene (20ml) benzylglyoxylate (1.070g) and Na₂SO₄ were added (2.5g). The mixture was refluxed overnight. After filtration the resulting solution was concentrated under vacuum to a brown oil, which was then taken up with dry dichloromethane (40ml). After cooling to -78°, TiCl₄ (0.57ml) was slowly added with a syringe and stirring continued for 5 min. The solution was then allowed to warm to room temperature over 30min by removing the dry ice/acetone bath, then cooled again to -78° and tributylallyltin (1.94 ml) added. After 1 hour the reaction was stopped by pouring it into a saturated solution of NH₄Cl (100ml). The aqueous phase was extracted with EA (2x200ml) and the combined organic fractions washed with HCl (3N, 2x70ml) and brine (50ml) and dried. Final purification by column chromatography (CH/EA 95/5) gave the title compound (1.05g) as a yellow oil.

20

25

30

¹H-NMR (CDCl₃): 7.4 - 7.3 (3H, m); 6.87 (1H, d); 6.27 (1H, d); 5.72 (1H, m); 5.22 - 5.16 (2H, m); 5.19 (2H, s); 5.14 (1H, d); 4.16 (1H, t); 2.65 (2H, m).
I.R. (neat): 3371cm⁻¹; 1744cm⁻¹; 1572cm⁻¹

35

Intermediate 9

(±) 2-(3,5-Dichloro-2-iodo-phenylamino)-4-oxo-butyric acid benzyl ester

Intermediate 8 (1.0g) was dissolved in dry dichloromethane (40ml) and the resulting solution cooled to -78° with a dry ice/acetone bath. Ozone was bubbled through it until a brick-red color appeared (approx 20min), then triphenylphosphine (0.82g) was added and the cooling bath removed. After the warm-up was complete the solution was concentrated to dryness and then purified by column chromatography (CH/EA 80/20) to give the title compound (0.745g) as a colorless oil.

10

¹H-NMR (CDCl₃): 9.77 (1H, s); 7.36 - 7.28 (5H, m); 6.91 (1H, d); 6.40 (1H, d); 5.34 (1H, d); 5.20 (2H, s); 4.50 (1H, dt); 3.09 (2H, d).
I.R. (nujol): 3371cm⁻¹; 1738cm⁻¹, 1732cm⁻¹

15

Intermediate 10**(±)(E)2-(3,5-Dichloro-2-iodo-phenylamino)-5-phenylcarbamoyl-pent-4-enoic acid benzyl ester**

20

Phenylcarbamoylmethyl triphenylphosphonium bromide (0.517g) was suspended in dry acetonitrile (20ml) and DBU (0.173ml) was added with stirring. The reaction mixture was cooled at 0° and intermediate 9 (0.460g) was added dissolved in dry acetonitrile (8ml). After 1h, a saturated solution of ammonium chloride (20ml) was added followed by ethyl acetate (30ml). The organic layer was separated, washed with brine (2x30ml), dried and evaporated under vacuum. The crude product was purified by flash chromatography (CH/EA 80/20) to give the title compound (0.250g) as white solid

25

30

¹H-NMR (CDCl₃): 7.54 (2H, s); 7.38 - 7.3 (7H, m); 7.13 (1H, t); 6.99 (1H, s); 6.90 (1H, d); 6.85 (1H, t); 6.32 (1H, d); 5.26 (1H, d); 4.28 (1H, d); 2.80 (2H, dt).
m.p. 146-148°.

Intermediate 11

35

(+/-)(E)5,7-Dichloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

Intermediate 10 (0.120g) was dissolved in dry acetonitrile (10ml) and the solution deoxygenated by bubbling through it dry N₂. To this solution, tetrakis(triphenylphosphine)palladium (0.012g) and triethylamine (0.056ml) were added and the reaction vessel sealed and heated to 80° for 2 hours. The brown mixture was then cooled, diluted with EA (100ml) and washed with a saturated solution of NH₄Cl (50ml). After drying with brine and with Na₂SO₄ the crude product was purified by column chromatography (CH/EA 7/3) to give the title compound (0.080g) as a pale yellow solid.

¹H-NMR (DMSO): 9.42 (1H, s); 7.75 (2H, d); 7.35 - 7.25 (7H, m); 7.07 (1H, tt); 6.78 (1H, s); 6.77 (1H, s); 6.70 (1H, d); 6.44 (1H, m); 5.12 (1H, d); 4.98 (1H, d); 4.40 (1H, ddd); 4.25 (1H, d); 3.15 (1H, d).
I.R. (nujol): 3281cm⁻¹; 1730cm⁻¹; 1661cm⁻¹, 1626cm⁻¹
m.p. 185-188°.

Intermediate 12

(+/-)(E)-5-(3,5-dichloro-2-iodo-phenylamino)-hex-2-endioic acid 6-benzyl ester

Intermediate 14 (0.2g) was dissolved in HCOOH (5ml) and stirred at room temperature for 24 h. The reaction mixture was then evaporated to dryness to give the title compound (0.180g).

¹H NMR (DMSO): 12.3 (bs, 1H); 7.4-7.3 (m, 5H); 7.01 (d, 1H); 6.73 (dt, 1H); 6.66 (d, 1H); 5.87 (d, 1H); 5.37 (d, 1H); 5.18 (s, 2H); 4.73 (dt, 1H); 2.81 (t, 1H).

Intermediate 13

(+/-)(E)-5-(3,5-dichloro-2-iodo-phenylamino)-1-(4-acetylamino-phenylcarbamoyl)-hex-2-endioic acid 6-benzyl ester

Intermediate 12 (0.18g) was dissolved in dry THF (5ml) under nitrogen and triphenylphosphine (0.11g) and Aldrithiol (0.092g) were subsequently added. After 2 hrs at RT, the commercial 4-acetamidoaniline was added at

RT and the mixture warmed till reflux. After 2 hrs the solution was reduced to small volume, poured into EA (20ml) and extracted with water. The crude was evaporated to dryness and columned (CH-EA 20:80) to give 150 mg of the title compound.

5

¹H NMR (DMSO): 9.94 (s, 1H); 9.86 (s, 1H); 7.53 (d, 2H); 7.47 (d, 2H); 7.35-7.3 (m, 5H); 7.24 (dt, 1H); 7.00 (d, 1H); 6.68 (d, 1H); 6.15 (d, 1H); 5.37 (d, 1H); 5.19 (s, 2H); 4.74 (m, 1H); 2.8 (m, 2H); 1.99 (s, 3H).

10 m.p. 200°C

Intermediate 14**(+/-)(E)-2-(3,5-dichloro-2-iodo-phenylamino)-hex-2-endioic acid-6-benzyl-1-tert-butylester**

15

Intermediate 9 (8.2g) was dissolved in dry toluene (200ml), then (tert-butoxycarbonyl methylene) triphenylphosphorane was added and the mixture was stirred at 100° for 2h. The solvent was removed under vacuum and the crude product was purified by flash-chromatography (CH/EA 95/5) to give the title compound (6.00g) as a white solid.

20

¹H-NMR (d₆-acetone): 7.4-7.3 (m,5H); 6.92 (d,1H); 6.82 (dt,1H); 6.67 (d,1H); 5.88 (dt,1H); 5.40 (d,1H); 5.24 (s,2H); 4.66 (dt,1H); 3.0-2.8 (m,2H); 1.5 (s,9H)

25 m.p. 95-96°C

Intermediate 15**(+/-)(E)-5,7-dichloro-4-tert-butoxycarbonylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

30

Intermediate 14 (6.5g) was dissolved in dry dimethylformamide (150ml). To this solution, tetrakis(triphenylphosphine)palladium (0.65g) and triethylamine (9.15ml) were added and the reaction mixture was heated to 100° for 1 h under nitrogen atmosphere. The reaction mixture was then cooled to room temperature, diluted with ethyl acetate (250ml), washed with

35

a saturated solution of aqueous NH_4Cl (100ml) and with brine (3x100ml). The organic layer was separated, dried, filtered and evaporated under vacuum. The crude product was purified by flash chromatography (EA/CH 1/9) to give the title compound (4g) as a white solid.

5

$^1\text{H-NMR}$ (DMSO): 7.44-7.3 (m, 5H); 6.77 (d, 1H); 6.70 (d, 1H); 6.47 (bs, 1H); 6.45 (s, 1H); 5.21 (d, 1H); 5.02 (d, 1H); 4.40 (td, 1H); 3.98 (dd, 1H); 3.11 (ddd, 1H); 1.5 (s, 9H).

10

Intermediate 16

(+/-)(E)-5,7 -dichloro-4-carboxymethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

15

Intermediate 15 (0.96g) was suspended in formic acid (40ml) and stirred at room temperature for 2 hours. The solvent was removed under vacuum, then the solid was suspended in ether and then concentrated again to dryness to give the title compound (0.86 mg) as a white solid.

20

$^1\text{H-NMR}$ (d_6 -acetone): 11.2-10.6 (bs, 1H); 7.4-7.3 (m, 5H); 6.78 (d, 1H); 6.71 (d, 1H); 6.57 (s, 1H); 6.49 (bs, 1H); 5.18 (d, 1H); 5.03 (d, 1H); 4.41 (t, 1H); 4.05-4 (m, 1H); 3.14 (ddd, 1H)

I.R.(Nujol): 3373cm^{-1} ; 1726cm^{-1} ; 1688cm^{-1} ; 1614cm^{-1}

m.p. $210-212^\circ\text{C}$

25

Intermediate 17

(+/-)(E)-5,7-dichloro-4-[2-(pyridyl)thiocarbonylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

30

Intermediate 16 (3.7g) was dissolved in dry tetrahydrofuran (50ml). To this solution, triphenylphosphine (6.17g) and 2,2'-dithiopyridine (5.2g) were added and the reaction mixture was stirred for 1 h at room temperature under nitrogen atmosphere. The reaction mixture was diluted with ethyl acetate (200ml), then washed with HCl 1N (50ml), NaOH 2M (50ml) and brine (2x50ml). The organic layer was separated, dried, filtered and

35

evaporated under vacuum. The crude product was purified by flash

chromatography (EA/CH 3/7) to give the title compound (3.5g) as a yellow foam.

5 ^1H -NMR(DMSO): 8.59 (m, 1H); 7.78 (dt, 1H); 7.62 (m, 2H); 7.45-7.27 (m, 5H); 6.84-6.76 (s, 3H); 5.15 (d, 1H); 4.97 (d, 1H); 4.40 (m, 1H); 3.92 (dd, 1H); 2.80 (m, 1H).

Intermediate 18

10 **(+/-)(E)-4-(4-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

15 Intermediate 13 (0.14g) was dissolved in dry acetonitril (11ml) under nitrogen and Pd tetrakis(triphenylphosphine) (0.012g) and TEA (0.06ml) were subsequently added. The suspension was stirred and warmed to reflux till completion of the reaction. After cooling a white solid precipitated to give the title compound (30mg) after filtration.

20 ^1H NMR (DMSO): 10.12 (s, 1H); 9.86 (s, 1H); 7.56 (d, 2H); 7.47 (d, 2H); 7.3-7.2 (m, 5H); 6.71 (d, 1H); 6.69 (d, 1H); 6.68 (bm, 1H); 5.05 (d, 1H); 4.85 (d, 1H); 4.35 (m, 1H); 4.25 (dd, 1H); 2.0(s, 3H).

m.p. 275°C

Intermediate 19

25 **(+/-)(E)-4-(3-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

30 Intermediate 16 (0.080g) was dissolved in dry tetrahydrofuran (7ml) and the solution was cooled to -20°C. At the same temperature PCl_5 (0.053g) was added and the reaction mixture was warmed to 0°C and stirred for 1 h under nitrogen atmosphere. Pyridine (0.025ml) and 3-acetylaminoaniline (0.035g) were then added and the reaction mixture was stirred for 3 h at room temperature. The reaction mixture was then diluted with ethyl acetate (50ml), washed with HCl 1 N (50ml), and with brine (50ml). The organic
35 layer was separated, dried, filtered and evaporated under vacuum to give a

crude product which was purified by flash chromatography (EA/CH 6:4) to give the title compound (0.045g) as a yellow oil.

5 ^1H NMR (DMSO): 10.19 (s, 1H); 9.93 (s, 1H); 7.99 (s, 1H); 7.24 (m, 5H); 7.38-7.16 (m, 4H); 6.73 (bs, 1H); 6.72 (d, 1H); 6.70 (d, 1H); 5.07-4.8 (d, 2H); 4.35 (m, 1H); 4.22 (m, 1H); 2.02 (s, 3H).

IR (nujol): 3304, 1732, 1668, 1600.

10 **Intermediate 20**

(+/-)(E)-5,7-dichloro-4-[3-(chloro)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

15 Intermediate 16 (0.11g) was dissolved in THF (10ml), the resulting solution was cooled at -20° and PCl_5 (0.10g) was added. The mixture was stirred for 1 hour at 0° , then the temperature was lowered to -20° and pyridine (0.045ml) and 3-chloro aniline (0.037ml) were added. The reaction was stirred at room temperature for 14 hours then diluted with EA (100ml) and washed with a saturated solution of NH_4Cl (2x50ml), with HCl 0.1N (50ml) and brine (50ml). The organic layer was dried, and evaporated under vacuum. The crude product was purified by flash-chromatography (CH/EA 9/1 to 8/2) to give the title compound (0.05g) as a yellow solid.

25 ^1H -NMR (DMSO): 10.36 (bs, 1H); 7.94 (bs, 1H); 7.43 (d, 1H); 7.33 (d, 1H); 7.28 (bd, 1H); 7.10 (dt, 1H); 7.24 (m, 5H); 6.72 (m, 3H); 5.03 (d, 1H); 4.85 (d, 1H); 4.38 (m, 1H); 4.26 (dd, 1H); 2.78 (dd, 1H)
I.R. (Nujol): 3340cm^{-1} ; 1732cm^{-1} ; 1659cm^{-1}

Intermediate 21

30 **(+/-)(E)-4-(4-amino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

35 Intermediate 23 (0.175g) was suspended in dry dichloromethane (5ml) and TFA (0.10ml) was added at RT and the solution stirred for 4h. The solution was evaporated to dryness to give a crude solid which was

dissolved in EA and washed with saturated sodium carbonate solution. The organic phase was evaporated to dryness to give a crude which was triturated with pentane giving the title compound (0.116g).

5

^1H NMR (DMSO): 9.79 (s, 1H); 7.31 (d, 2H); 7.3-7.2 (m, 5H); 7.19 (d, 1H); 6.70 (d, 1H); 6.69 (d, 1H); 6.64 (m, 1H); 6.48 (d, 2H); 5.05 (d, 1H); 4.85 (d, 1H); 4.33 (m, 1H); 4.24 (dd, 1H); 2.80 (s, 1H).

10 m.p. 80°C

Intermediate 22**4,6-dibromo-1-iodo-2-nitrobenzene**

2-nitro-4,6-dibromoaniline (2g) was dissolved in a 12N solution of H_2SO_4 (14ml) and cooled at 0°. Then, a solution of NaNO_2 (0.6g) in H_2SO_4 (5ml) was carefully added followed by PPA (10ml). The reaction mixture was allowed to warm at room temperature and stirred for 3hrs. Then, the solution was poured into crushed ice and urea was added until gas evolution ceases.

20 The resulting mixture was treated with an aqueous solution of potassium iodide (1.6g) and heated at 70° for 2hrs. The reaction mixture was diluted with a 10% solution of sodium hydroxide (20ml), extracted with ethyl acetate (3x20ml), washed with brine (3x15ml), dried and concentrated under vacuum. The title compound was obtained as a yellow solid (2.6g).

25

^1H -NMR (CDCl_3): 7.98 (1H, d); 7.60 (1H, d);
I.R.(nujol): 1529 cm^{-1} , 1377 cm^{-1} .
m.p. (°C): 68°C - 70°C

30

Intermediate 23**(+/-)(E)-4-(4-tert-butoxycarbonylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

35

Intermediate 16 (0.157g) was dissolved in dry THF (8ml) and the solution cooled to -20° . PCl_5 (0.104g) was added and the solution stirred for 1h. Pyridine (0.05ml) was added and then 4-t-Butoxycarbonylaminobenzylamine (0.104g) was added in one portion. The solution became orange and was warmed to RT. After 3hrs the solution was acidified to pH=3, extracted with EA and evaporated to dryness to give a crude solid which was triturated with pentane/diethyl ether to give the title compound (0.181g).

^1H NMR (DMSO): 9.35 (bs, 1H); 8.23 (bs, 1H); 7.66 (m, 2H); 7.48 (m, 2H); 7.35-7.28 (m, 5H); 6.76 (m, 2H); 6.68 (d, 1H); 6.42 (bs, 1H); 5.13 (d, 1H); 4.97 (d, 1H); 4.39 (t, 1H); 4.23 (dd, 1H); 3.18 (dd, 1H); 1.48 (s, 9H).

Intermediate 24

(+/-)(E)-5,7-dichloro-4-[4(tert-butoxycarbonylaminomethyl)phenylcarbonyl methylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

Intermediate 16 (0.57g) was dissolved in THF (15ml), the resulting solution was cooled at -20° and PCl_5 (0.38g) was added. The mixture was stirred for 1 hour at 0° , then the temperature was lowered to -20° and pyridine (0.176ml) and N-t-butoxycarbonyl-4-amino benzylamine (0.39g) were added. The reaction was stirred at room temperature for 30 min then diluted with EA (100ml) and washed with a saturated solution of NH_4Cl (2x50ml), with HCl 0.1N (50ml) and brine (50ml). The organic layer was dried and evaporated under vacuum. The crude product was purified by flash-chromatography (CH/EA 8/2 to 7/3) to give the title compound (0.72g) as a white solid.

^1H -NMR (d_6 -acetone): 9.42 (bs, 1H); 7.69 (d, 2H); 7.33 (dd, 2H); 7.3-7.27 (m, 3H); 7.26 (d, 2H); 6.78 (d, 1H); 6.77 (s, 1H); 6.69 (d, 1H); 6.44 (d, 1H); 6.42 (t, 1H); 5.12 (d, 1H); 4.97 (d, 1H); 4.40 (td, 1H); 4.25 (dd, 1H); 4.23 (d, 1H); 3.13 (ddd, 1H); 1.42 (s, 9H)

I.R. (Nujol): 3368cm^{-1} ; 3304cm^{-1} ; 1717cm^{-1}

Intermediate 25

(+/-)(E)-5,7-dichloro-4-[4-(2-tert-butoxycarbonylamino-ethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

- 5 Intermediate 17 (0.3g) was dissolved in dry tetrahydrofuran (20ml) and toluene (20ml). To this solution, 4-(2-tert-butylamino-ethyl)aniline (0.175g) was added and the reaction mixture was stirred for 2 h at 110 °. The reaction mixture was then diluted with ethyl acetate (50ml), washed with a HCl 0.1 N (50ml), and with brine (50ml). The organic layer was separated, dried, filtered and evaporated under vacuum to give a crude product which
10 was purified by flash chromatography (EA/CH 3:7) to give the title compound (0.360g) as a yellow solid.

- ¹H NMR (DMSO): 10.12 (s, 1H); 7.55 (d, 2H); 7.24 (m, 5H); 7.10 (d, 2H);
15 6.85 (t, 1H); 6.70 (m, 3H); 5.04-4.84 (d, d, 2H); 4.35 (m, 1H); 4.25 (m, 1H); 3.10 (m, 2H); 2.79 (m, 1H); 2.62 (t, 2H); 1.34 (s, 9H).

IR (nujol): 3368, 3298, 1700, 1686.

- 20 **Intermediate 26**
(+/-)(E)-5,7-dichloro-4-[4(ureidomethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

- Intermediate 24 (0.36g) was suspended in dry dichloromethane (20ml), then
25 trifluoroacetic acid (7.5ml) was added and the reaction was stirred at room temperature for 1 hour. The solvent was removed under vacuum to give a solid which was suspended in ether and evaporated to dryness. This solid was dissolved in dry THF (50ml), then dry TEA (0.14ml) was added and the mixture stirred at room temperature for 1.5 hours. The reaction was then
30 cooled to 0° and trimethylsilyl isocyanate (0.164ml) was dropped in. After 1 hour the reaction was stopped by pouring it into a saturated solution of NH₄Cl (50ml). The aqueous phase was extracted with EA (100ml), washed with brine (50ml) and evaporated under vacuum. The crude product was purified by flash-chromatography (EA to EA/MeOH 95/5) to give the title
35 compound (0.14g) as a yellow solid.

¹H-NMR (DMSO): 10.15(s,1H); 7.58(d,2H); 7.25 (bm,5H); 7.24 (m,1H); 7.17(d,2H); 6.71 (m,3H); 6.33 (bt,3H); 5.48 (bs,2H); 5.06 (d,1H); 4.85(d,1H); 4.36 (mt,1H); 4.25 (dd,1H); 4.11 (m,2H); 2.81 (ddd,1H)

5

Intermediate 27**(+/-)(E)-5,7-dichloro-4-****[4(formylaminomethyl)phenylcarbomoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

10

Intermediate 24 (0.18g) was dissolved in formic acid (10ml) and stirred at room temperature for 15 min. The solvent was removed under vacuum to give a solid which was suspended in ether and evaporated to dryness. This solid was dissolved in dry THF (10ml), then dry TEA (0.09ml) was added and the mixture stirred at room temperature for 30 min. The reaction was then cooled to 0° and methanesulphonylchloride (0.025ml) was dropped in. After 30 min the reaction was stopped by pouring it into a saturated solution of NH₄Cl (50ml). The aqueous phase was extracted with EA (100ml), washed with brine (50ml), dried and evaporated under vacuum. The crude product was purified by flash-chromatography (CH/EA 1/1) to give the title compound (0.050g) as a byproduct.

15

20

¹H-NMR (DMSO): 10.2 (bs,1H); 8.44 (t,1H); 8.10 (d,1H); 7.60 (d,2H); 7.26-7.20 (m,6H); 7.18 (d,2H); 6.72-6.68 (m,3H); 5.04 (d,1H); 5.40 (d,1H); 4.35 (m,1H); 4.25 (m,1H); 4.23 (d,2H); 2.80 (dd,1H)

25

Intermediate 28**(+/-)(E)-5,7-dichloro-4-****[4(acetylaminomethyl)phenylcarbomoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

30

Intermediate 24 (0.08g) was dissolved in dry dichloromethane (10ml), then trifluoroacetic acid (1ml) was added and the reaction was stirred at room temperature for 2 hour. The solvent was removed under vacuum to give a

35

solid which was suspended in ether and evaporated to dryness. This solid was dissolved in dry THF (15ml), then dry TEA (0.04ml) was added and the mixture stirred at room temperature for 1 hour. The reaction was then cooled to 0° and acetylchloride (0.01ml) was dropped in. After 40 min the reaction was stopped by pouring it into a saturated solution of NH₄Cl (50ml). The aqueous phase was extracted with EA (100ml), washed with brine (50ml), dried and evaporated under vacuum. The crude product was purified by flash-chromatography (EA/CH 9/1) then the solid was suspended in EA, petroleum ether was added and the solid was filtered to give the title compound (0.045g) as a yellow solid.

¹H-NMR (d₆-acetone): 9.41 (bs, 1H); 7.68 (d, 2H); 7.5-7.25 and 7.24 (m, 6H); 6.77 (d, 1H); 6.76 (bs, 1H); 6.69 (d, 1H); 6.44 (bs, 1H); 5.12 and 4.96 (d, 2H); 4.39 (m, 1H); 4.32b(d, 2H); 4.25 (dd, 1H); 3.14 (ddd, 1H)

Intermediate 29

(+/-)(E)-5,7-dichloro-4-[4(isobutylamino)phenyl]carbomoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

Intermediate 23 (0.15g) was dissolved in dry dichloromethane (20ml), then trifluoroacetic acid (2ml) was added and the reaction was stirred at room temperature for 2 hour. The solvent was removed under vacuum to give a solid which was suspended in ether and evaporated to dryness. This solid was dissolved in dry THF (20ml), then dry TEA (0.08ml) was added and the mixture stirred at room temperature for 1 hour. The reaction was then cooled to 0° and isobutylchloride (0.03ml) was dropped in. After 40 min the reaction was stopped by pouring it into a saturated solution of NH₄Cl (50ml). The aqueous phase was extracted with EA (100ml), washed with brine (50ml), dried and evaporated under vacuum. The crude product was purified by flash-chromatography (EA/CH 2/3) to give the title compound (0.040g) as a yellow solid.

¹H-NMR (DMSO): 10.11 (bs, 1H); 9.74 (bs, 1H); 7.56 (d, 2H); 7.52 (d, 2H); 7.26(m, 5H); 7.22 (d, 1H); 6.70 (m, 3H); 5.04 (d, 1H); 4.86 (d, 1H); 4.36 (m, 1H); 4.25 (m, 1H); 2.83(m, 1H); 2.51 (m, 1H); 1.07 (d, 6H)

I.R.(Nujol): 3387cm⁻¹; 3292cm⁻¹; 1715cm⁻¹; 1661cm⁻¹; 1658cm⁻¹

Intermediate 30

(+/-)(E)-5,7-dichloro-4-

5 **[4(isobutrylaminomethyl)phenylcarbamoylmethylene]-1,2,3,4-**
tetrahydro-quinoline-2-carboxylic acid benzyl ester

Intermediate 24 (0.36g) was suspended in dry dichloromethane (20ml), then trifluoroacetic acid (7.5ml) was added and the reaction was stirred at room temperature for 1 hour. The solvent was removed under vacuum to give a solid which was suspended in ether and evaporated to dryness. This solid was dissolved in dry THF (50ml), then dry TEA (0.23ml) was added and the mixture stirred at room temperature for 1.5 hours. The reaction was then cooled to 0° and isobutrylchloride (0.09ml) was dropped in. After 1 hour the reaction was stopped by pouring it into a saturated solution of NH₄Cl (50ml). The aqueous phase was extracted with EA (100ml), washed with brine (50ml) and evaporated under vacuum. The crude product was purified by flash-chromatography (CH/EA 6/4 to 1/1) and triturated with petroleum ether to give the title compound (0.14g) as a yellow solid.

20 ¹H-NMR (d₆-acetone): 9.42 (bs,1H); 7.68 (d,2H); 7.35 (bm,1H); 7.34 (dd,2H); 7.28 (m,3H); 7.23 (d,2H); 6.77 (d,1H); 6.76 (bs,1H); 6.69 (d,1H); 6.44 (d,1H); 5.12 (d,1H); 4.96 (d,1H); 4.40 (td,1H); 4.34 (d,2H); 4.25 (dd,1H); 4.23(d,1H); 3.13 (ddd,1H); 1.42 (s,9H)

25 I.R.(Nujol): 3368-3290cm⁻¹; 1724cm⁻¹; 1647cm⁻¹;1591cm⁻¹

Intermediate 31

(+/-)(E)-5,7-dichloro-4-(4-morpholin-4-

30 **ylmethylphenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-**
carboxylic acid, benzyl ester

To a stirred solution of intermediate 17 (0.15g) in dry tetrahydrofuran (10ml) was added 4-morpholin-4-ylmethyl-phenylamine (0.09g) and the reaction mixture was heated at reflux for 4 hrs. The solvent was evaporated, the residue was dissolved in toluene (10ml) and the solution was heated at

reflux for 1 hrs. The reaction mixture was cooled at 24°, affording a precipitate which was filtered to obtain the pure title compound (0.11g).
T.l.c. ethyl acetate, R_f =0.42.

- 5 $^1\text{H-NMR}$ (DMSO): 10.17(s, 1H), 7.60(d, 2H), 7.21(m, 8H), 6.72-6.70(m, 3H), 5.03(d, 1H), 4.83(d, 1H), 4.36(m, 1H), 4.25(dd, 1H), 3.54(t, 4H), 3.38(s, 2H), 2.8(dd, 1H), 2.30(m, 4H).

Intermediate 32

- 10 **(+/-)(E)-4-(4-methoxycarbonylmethyl-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester**

- 15 Intermediate 17 (0.121g) was dissolved in dry toluene (10ml). To this solution, methyl 4-(aminophenyl)acetate (0.052g) was added and the reaction mixture was refluxed for 1 h. The reaction mixture was then cooled and a precipitate was formed which was filtered and washed with diethyl ether to give the title compound (0.099g) as a yellow solid.

- 20 $^1\text{H NMR}$ (DMSO): 10.2 (s, 1H); 7.59 (d, 2H); 7.26-7.2 (m, 6H); 7.18 (d, 2H); 6.72-6.70 (m, 3H); 5.04 (d, 1H); 4.84 (d, 1H); 4.36 (m, 1H); 4.25 (dd, 1H); 3.61 (s, 2H); 3.59 (s, 3H); 2.79 (dd, 1H).

IR (nujol): 3358, 3308, 1722, 1649.

25

Intermediate 33

(+/-)(E)-5,7-dichloro-4-(4-carbamoylmethyl-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

30

Intermediate 17 (0.2g) was dissolved in dry dimethylformamide (30ml). To this solution, 4-carbamoylmethylaniline (0.073g) was added and the reaction mixture was stirred for 2 h at 100 °. The reaction mixture was then diluted with ethyl acetate (50ml), washed with a saturated aqueous solution of NH_4Cl (50ml), and with brine (50ml). The organic layer was

35

separated, dried, filtered and evaporated under vacuum to give a crude product which was triturated in ethyl acetate (5ml) and petroleum ether (20ml) to give the title compound (0.150g) as a yellow solid.

- 5 ^1H NMR (DMSO): 10.2 (bs, 1H); 7.56 (d, 2H); 7.40 (bs, 1H); 7.26-7.20 (m, 6H); 7.17 (d, 2H); 6.84 (bs, 1H); 6.72-6.70 (m, 3H); 5.04 (d, 1H); 4.84 (d, 1H); 4.35 (m, 1H); 4.25 (dd, 1H); 2.79 (dd, 1H);

IR (nujol): 3366, 3287, 1715, 1653.

10

Intermediate 34

(+/-)(E)-5,7-dichloro-4-[4-(2-isobutirylamino-ethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

15

Intermediate 17 (0.2g) was dissolved in dry tetrahydrofuran (15ml) and dry toluene (15ml). To this solution, 4-(2-tert-butoxycarbonylaminoethyl)aniline (0.127g) was added and the reaction mixture was heated for 2 h at 110°.

- 20 The reaction mixture was then diluted with ethyl acetate (50ml), washed with HCl 0.1 N (50ml) and with brine (50ml). The organic layer was separated, dried, filtered and evaporated under vacuum to give a yellow oil (0.4g) that was dissolved in dry dichloromethane (10ml). To this solution, trifluoroacetic acid (1ml) was added and the reaction mixture was stirred for 2 h at room temperature under nitrogen atmosphere and then evaporated under vacuum
- 25 to give a dark yellow oil that was dissolved in dry tetrahydrofuran (10ml).

- Triethylamine (0.073ml) was then added and the solution was stirred for 1 h at room temperature; isobutiryl chloride (0.052ml) was then added and the resulting reaction mixture was stirred for 2 h at room temperature. The reaction mixture was then diluted with ethyl acetate (50ml), washed with a
- 30 saturated aqueous solution of NH_4Cl (50ml) and with brine (50ml). The organic layer was separated, dried, filtered and evaporated under vacuum to give the title compound (0.120g) as a yellow solid.

- ^1H NMR (DMSO): 10.12 (s, 1H); 7.74 (t, 1H); 7.56 (d, 2H); 7.24 (m, 5H);
- 35 7.11 (d+s, 3H); 6.70 (m, 3H); 5.05 (d, 1H); 4.85 (d, 1H); 4.36 (m, 1H); 4.25

(dd, 1H), 3.21 (m, 2H); 2.80 (dd, 1H); 2.63 (m, 2H); 2.28 (m, 1H); 0.94 (d, 6H).

m.p. 180-182 °C

5

Intermediate 35

(+/-)(E)-5,7-dichloro-4-[4-(2-acetylamino-ethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid benzyl ester

10

Intermediate 25 (0.180g), was dissolved in dry dichloromethane (10ml). To this solution, trifluoroacetic acid (2ml) was added and the reaction mixture was stirred for 2 h at room temperature under nitrogen atmosphere and then evaporated under vacuum to give a dark yellow oil that was dissolved in dry tetrahydrofuran (10ml). Triethylamine (0.088ml) was then added and the solution was stirred for 1 h at room temperature; acetyl chloride (0.025ml) was then added and the resulting reaction mixture was stirred for 3 h at room temperature. The reaction mixture was then diluted with ethyl acetate (50ml), washed with a saturated aqueous solution of NH₄Cl (50ml) and with brine (50ml). The organic layer was separated, dried, filtered and evaporated under vacuum to give the title compound (0.110g) as a white solid.

¹H NMR (DMSO): 10.129 (s, 1H); 7.88 (t, 1H); 7.56 (d, 2H); 7.24 (m, 5H); 6.71 (d, 1H) 6.70 (d, 1H); 6.70 (bs, 1H); 6.12 (d, 2H); 5.05 (d, 1H); 4.85 (d, 1H); 4.35 (m, 1H); 4.24 (m, 1H); 3.21 (m, 2H); 2.83 (m, 1H); 2.63 (m, 2H); 1.76 (s, 3H).

25

m.p. 235-238°C

30

IR (nujol): 3288, 1747, 1724, 1624-1600.

Intermediate 36

N-(4-t-butoxycarbonylamino-phenyl)-3-methyl-butyramide

35

To a stirred solution of N-t-butoxycarbonyl-1,4-phenylene diamine (0.2g) in dry tetrahydrofuran (20ml) were added pyridine (0.15ml) and 3-methylbutyryl chloride (0.13g) and the reaction mixture was stirred for 1 hrs. The solution was diluted with ethyl acetate (50ml), washed with a 3N
5 solution of hydrochloric acid (30ml) and brine (30ml), dried and concentrated in vacuum to give the title compound (0.27g). T.l.c. cyclohexane/ethyl acetate 1/1, $R_f=0.71$.

¹H-NMR(CDCl₃): 7.43(d, 2H), 7.30(d, 2H), 7.05(bs, 1H), 6.43(bs, 1H), 2.25-
10 2.18(m, 3H), 1.51(s, 9H), 1.01(d, 6H).

Intermediate 37

N-(4-aminophenyl)-3-methyl-butylamide

15 A solution of intermediate 36 (0.27g) in dichloromethane/trifluoroacetic acid (5ml/5ml) was stirred for 45 min. The solvent was evaporated, the crude product was diluted with ethyl acetate (50ml), washed with a 5% solution of sodium hydroxyde (30ml) and brine (30ml), dried and concentrated in vacuum. The crude product was purified by silica gel column
20 chromatography using ethyl acetate as eluant to give the title compound (0.177g). T.l.c. ethyl acetate, $R_f=0.52$.

¹H-NMR(DMSO): 9.37(s, 1H), 7.18(d, 2H), 6.45(d, 2H), 4.80(s, 2H), 2.1-
25 1.95(m, 3H), 0.89(d, 6H).

Intermediate 38

(+/-)-(E)-5,7-dichloro-4-[4-(3-methyl-butylamino)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid, benzyl ester

30 To a stirred solution of intermediate 17 (0.05g) in dry toluene (6ml) was added intermediate 37 (0.043g) and the reaction mixture was heated at reflux for 1 hrs. The reaction mixture was cooled at 24°, affording a precipitate which was filtered to obtain the pure title compound (0.05g).
35 T.l.c. EA/CH 1/1, $R_f=0.62$.

1H-NMR(DMSO): 10.12(s, 1H), 9.78(s, 1H), 7.56(d, 2H), 7.50(d, 2H),
7.25(m, 6H), 6.71(d, 1H), 6.69(d, 1H), 6.69(s, 1H) 5.06(d, 1H), 4.85(d, 1H),
4.33(m, 1H), 4.25(dd, 1H), 2.82(dd, 1H), 2.14(d, 2H), 2.05(m, 1H), 0.91(d,
5 6H).

Intermediate 39

2-iodo-3,5-dibromoaniline

10 Intermediate 22 (1.5g) was dissolved in 95% ethanol (12ml) and glacial
acetic acid (12ml) and iron (0.823g) was added. The reaction mixture was
heated at 100° for 1 h then diluted with a saturated solution of sodium
hydrogencarbonate and extracted with ethyl acetate (3x10ml). The organic
layer was washed with brine (2x10ml), dried, evaporated under vacuum to
15 give the title compound as brown oil (1.15g).

¹H-NMR (CDCl₃): 7.20 (1H, d); 6.80 (1H, d); 4.40 (2H, bs).

I.R.(nujol): 1609cm⁻¹, 1580 cm⁻¹, 1592 cm⁻¹

20 **Intermediate 40**

(+/-)-2-(3,5-dibromo-2-iodo-phenylamino)-pent-4-enoic acid benzyl ester

To a solution of 2-iodo-3,5-dibromoaniline (1.1g) in dry toluene (20ml) were
added benzylglyoxylate (0.530g) and Na₂SO₄ (1g). The mixture was
25 refluxed overnight. After filtration the resulting solution was concentrated
under vacuum to a brown oil, which was then taken up with dry
dichloromethane (20ml). After cooling to -78°, TiCl₄ (0.318ml) was slowly
added with a syringe and stirring continued for 5 min. The solution was then
allowed to warm to room temperature over 30min by removing the dry
30 ice/acetone bath, then cooled again to -78° and tributylalyltin (0.98 ml)
added. After 1 hour the reaction was stopped by pouring it into a saturated
solution of NH₄Cl (80ml). The aqueous phase was extracted with EA
(2x100ml) and the combined organic fractions washed with HCl (3N,
2x30ml) and brine (50ml) and dried. Final purification by column
35 chromatography (CH/EA 8/2) gave the title compound (0.6g) as a yellow oil.

¹H-NMR (CDCl₃): 7.4 - 7.3 (3H, m); 6.87 (1H, d); 6.27 (1H, d); 5.72 (1H, m); 5.22 - 5.16 (2H, m); 5.19 (2H, s); 5.14 (1H, d); 4.16 (1H, t); 2.65 (2H, m).
I.R. (neat): 3371cm⁻¹; 1744cm⁻¹; 1572cm⁻¹

5

Intermediate 41

(+/-)-2-(3,5-dibromo-2-iodo-phenylamino)-4-oxo-butyric acid benzyl ester

- 10 Intermediate 40 (0.45g) was dissolved in dry dichloromethane (20ml) and the resulting solution cooled to -78° with a dry ice/acetone bath. Ozone was bubbled through it until a brick-red color appeared (approx 20min), then triphenylphosphine (0.4g) was added and the cooling bath removed. After the warm-up was complete the solution was concentrated to dryness on the
15 rotary evaporator and finally purified by column chromatography (CH/EA 80/20) to give the title compound (0.22g) as a colorless oil.

- ¹H-NMR (DMSO): 9.64 (1H, t); 7.26 - 7.36 (5H, m); 7.21 (1H, d); 6.87 (1H, d); 5.63 (1H, d); 5.13 (2H, s); 4.91 (1H, dt); 3.17 (1H, ddd); 3.09 (1H, ddd).
20 I.R. (nujol): 3371cm⁻¹; 1738cm⁻¹; 1732cm⁻¹

Intermediate 42

(+/-)-(E)-2-(3,5-dibromo-2-iodo-phenylamino)-5-phenylcarbamoyl-pent-4-enoic acid benzyl ester

25

- Phenylcarbamoylmethylene triphenylphosphonium bromide (0.2g) was suspended in dry acetonitrile (15ml) and DBU (0.066ml) was added with stirring. The reaction mixture was cooled at 0° and intermediate 41 (0.210g) was added dissolved in dry acetonitrile (8ml). After 1h, a saturated solution of
30 ammonium chloride (10ml) was added followed by ethyl acetate (30ml). The organic layer was separated, washed with brine (2x10ml), dried and evaporated under vacuum. The crude product was purified by flash chromatography (CH/EA 70/30) to give the title compound (0.150g) as white solid (pure E isomer).

35

¹H-NMR (CDCl₃): 7.54 (2H, bd); 7.4 - 7.3 (7H, m); 7.13 (1H, t); 7.00 (1H, s); 6.90 (1H, s); 6.85 (1H, dt); 6.49 (1H, d); 5.26 (1H, d); 4.28 (1H, d); 2.77 - 2.83 (2H, m).

m.p. (°C): 168-170°C

5

Intermediate 43

(+/-)-(E)-5,7-dibromo-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydroquinoline-2-carboxylic acid benzyl ester

- 10 Intermediate 42 (0.130g) was dissolved in dry acetonitrile (10ml) and the solution deoxygenated by bubbling through it dry N₂. To this solution, Pd(PPh₃)₄ (0.011g) and triethylamine (0.053ml) were added and the reaction vessel sealed and heated to 80° for 4 hours. The brown mixture was then cooled, diluted with EA (100ml) and washed with a saturated
- 15 solution of NH₄Cl (50ml). After drying with brine and with Na₂SO₄ the crude product was purified by column chromatography (CH/EA 75/25) to give the title compound (0.048g) as a pale yellow solid.

- 20 ¹H-NMR (DMSO): 9.45 (1H, s); 7.77 (2H, m); 7.35 - 7.28 (7H, m); 7.07 (1H, m); 7.02 (1H, d); 6.96 (1H, d); ; 5.12 (1H, d); 4.96 (1H, d); 4.40 (1H, m); 4.22 (1H, dd); 3.17 (1H, ddd).

m.p. (°C) 184-186°C

25 **Example 1**

(+/-)-(E)-7-Chloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydroquinoline-2-carboxylic acid

- 30 To the stirred solution of Intermediate 5 (0.035g) in 4/1 EtOH/H₂O (2ml) LiOH·H₂O (0.007g) was added. Stirring was continued at room temperature for 1.5 hours. After concentrating the solution to approximately 0.5ml, HCl (3N, 5ml) was added and the precipitate thus formed filtered, washed with small amounts of cold water and dried under vacuum to give the title compound (0.022g) as a yellow solid.

¹H NMR: d (CDCl₃) 12.71 (bs, 1H), 10.01 (bs, 1H), 7.62 (m, 2H), 7.38 (d, 1H), 7.29 (m, 2H), 7.01 (m, 1H), 6.80 (bd, 1H), 6.78 (d, 1H), 6.59 (dd, 1H), 6.49 (s, 1H), 4.03 (t, 1H), 3.71 (dd, 1H), 3.35 (m, 1H).
m.p. 118-120°.

5

Example 2**(+/-)(E)7-Chloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid sodium salt**

10 Example 1 (0.019g) was suspended in water and NaOH (0.1N, 0.55ml) was added with stirring. After 30 min the suspension was cooled to -40° and lyophilized for 24 hours. The title compound (15mg) was isolated as a yellow solid.

¹H NMR: d (CDCl₃) 10.89 (bs, 1H), 7.70 (d, 2H), 7.30 (d, 1H), 7.27 (t, 2H),
15 6.99 (t, 1H), 6.77 (d, 1H), 6.42 (dd, 1H), 6.37 (bs, 1H), 6.25 (s, 1H), 3.25-3.42 (m, 2H), 2.69 (m, 1H).

IR: (nujol) $\nu_{\max}$ (cm⁻¹) 3180-3500, 1651, 1599

Example 3**(+/-)(E)5,7-dichloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid**

To the stirred solution of intermediate 11 (0.016g) in 4/1 EtOH/H₂O (2ml) LiOH·H₂O (0.003g) was added. Stirring was continued at room temperature
25 for 30min. After concentratin the solution to approximately 0.5ml, HCl (3N, 5ml) was added and the precipitate thus formed filtered, washed with small amounts of cold water and dried under vacuum to give the title compound (0.008g) as a pale yellow solid.

30 ¹H-NMR (DMSO): 12.71 (1H, s); 10.13 (1H, s); 7.63 (2H, d); 7.29 (2H, t); 7.03 (1H, t); 6.70 (1H, s); 6.69 (1H, m); 6.68 (1H, m); 4.12 (1H, t); 3.90 (1H, dd); 3.64 (1H, dd).

I.R.: (nujol): 3377cm⁻¹, 3200-3600cm⁻¹, 1726cm⁻¹.

35 Example 4

(+/-)(E)5,7-dichloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid sodium salt

5 Example 3 (0.019g) was suspended in water and NaOH (0.1N, 1.06ml) was added with stirring. After 30 min the suspension was cooled to -40° and lyophilized for 24 hours. The title compound (41mg) was isolated as a yellow solid.

¹H-NMR(DMSO): 11.37(s, 1H); 7.74(d, 2H); 7.28(m, 2H); 7.00(m, 2H); 6.73(d, 1H); 6.71(m, 1H); 6.52(s, 1H); 6.49(d, 1H); 3.49(m, 1H); 3.28(m, 1H); 2.64(m, 1H)

Example 5

(+/-)(E)-4-(4-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

15 Intermediate 18 (0.027g) was dissolved in a 2/1 mixture of EtOH and water (5ml) and LiOH monohydrate (0.009g) was added. The suspension was stirred and warmed to 60° for 40 min. After cooling the solution was acidified with 2N HCl (2ml) giving the title compound as a light yellow solid (0.016g) after filtration.

¹H NMR (DMSO): 10.71 (bs, 1H); 10.08 (s, 1H); 9.86 (s, 1H); 7.54 (d, 2H); 7.48 (d, 2H); 7.10 (d, 1H); 6.69 (d, 1H); 6.67 (m, 2H); 4.10 (dt, 1H); 3.88 (dd, 1H); 3.05 (dd, 1H); 2.0 (s, 3H).

m.p. 185°C

Example 6

30 **(+/-)(E)-4-(3-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid**

Intermediate 19 (0.045g) was suspended in ethanol (5ml) and water (2.5ml). To this solution, LiOH(H₂O) (0.007g) was added and the reaction mixture 35 was stirred for 1 h at 50° until a clear pale yellow solution was obtained.

HCl 2 N (5ml) was then added dropwise and the resulting acidic solution diluted with water (30ml); the precipitate thus formed was filtered, washed with small amounts of cold water and dried to give the title compound (0.013g) as a yellow solid.

5

¹H NMR (DMSO): 12.74 (bs, 1H); 10.15 (s, 1H); 9.94 (s, 1H); 7.97 (s, 1H); 7.31 (d, 1H); 7.29 (d, 1H); 7.12 (d, 1H); 6.72 (bs, 1H); 6.69 (d, 1H); 6.68 (d, 1H); 4.12 (m, 1H); 3.9 (m, 1H); 3.06 (m, 1H); 2.02 (s, 3H).

10 m. p.: 190-193 °C

m.p. 215°C

Example 715 **(+/-)(E)-5,7-dichloro-4-[3-(chloro)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid**20 Intermediate 20 (0.02g) was suspended in EtOH /H₂O (2/1), then LiOH·H₂O (5mg) was added and the reaction was stirred at room temperature for 30 min. The solution was acidified with HCl 2 N and then extracted with EA, the organic layer was washed with water, dried and the solvent was removed under vacuum. The solid was suspended in water and filtered to give the title compound (0.013g) as a yellow solid.25 ¹H-NMR (DMSO): 12.73 (bs,1H); 10.35 (bs,1H); 7.69 (t,1H); 7.46 (m,1H); 7.33(m,1H); 7.10 (m,1H); 7.16 (m,1H); 6.71 (d,1H); 6.69 (d,1H); 6.69 (bs,1H); 4.13 (m,1H); 3.89(m,1H); 3.02 (m,1H)
I.R.(Nujol): 3402cm⁻¹; 1718cm⁻¹; 1659cm⁻¹30 **Example 8****(+/-)(E)-4-(4-amino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid**

35 Intermediate 21 (0.110g) was dissolved in a 1/1 mixture of EtOH and water (3ml) and LiOH monohydrate (0.058g) was added. The suspension was

stirred at RT for 2hrs. The solution was acidified with 2N HCl giving the title compound as a light yellow solid (0.060g) after filtration.

¹H NMR (DMSO): 12.60 (bm, 1H); 9.79 (bs, 1H); 7.33 (d, 2H); 7.07 (bm, 1H); 6.85-6.5 (m, 4H); 4.10 (m, 1H); 3.86 (dd, 1H); 3.09 (dd, 1H).

m.p. >250°C

Example 9

(+/-)(E)-5,7-dichloro-4-[4(ureidomethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

Intermediate 26 (0.14g) was suspended in EtOH /H₂O (2/1), then LiOH·H₂O (44mg) was added and the reaction was stirred at room temperature for 1 hour. The solution was concentrated, diluted with water and acidified with HCl 2N. The precipitate obtained was filtered and washed with water to give the title compound (0.084g) as a yellow solid.

¹H-NMR (DMSO): 12.71 (bs,1H); 10.11 (bs,1H); 7.57 (d,2H); 7.17 (d,2H); 7.11 (bs,1H); 6.7 (m,3H); 6.34 (t,1H); 5.48 (bs,2H); 4.11 (d,2H); 4.12 (m,1H); 3.88(dd,1H); 3.07(dd,1H)

I.R.(Nujol): 3474,3418,3287cm⁻¹; 1728cm⁻¹; 1664cm⁻¹;1641cm⁻¹;1620cm⁻¹

m.p.>.230°C

Example 10

(+/-)(E)-5,7-dichloro-4-[4(formylaminomethyl)phenyl carbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

Intermediate 27 (0.050g) was suspended in EtOH /H₂O (2/1), then LiOH·H₂O (14.6mg) was added and the reaction was stirred at room temperature for 2 hours. The solution was concentrated, diluted with water and acidified with HCl 1N. The precipitate obtained was filtered and washed with water to give the title compound (0.040g) as a yellow solid.

- ¹H-NMR (DMSO): 12.73 (bs,1H); 10.15 (s,1H); 8.44 (t,1H); 8.10 (d,1H); 7.58 (d,2H); 7.18 (d,2H); 7.11(d,1H); 6.70-6.66 (m,3H); 4.83 (d,2H); 4.10 (m,1H); 3.86 (dd,1H); 3.06(dd,1H)
- 5 I.R.(Nujol): 3406cm⁻¹; 3344cm⁻¹; 1720cm⁻¹

Example 11**(+/-)(E)-5,7-dichloro-4-**

- 10 **[4(acetylaminomethyl)phenylcarbomoylmethylene]-1,2,3,4-tetrahydro-**
quinoline-2-carboxylic acid

- Intermediate 28 (0.045g) was suspended in EtOH /H₂O (3/1), then LiOH·H₂O (14mg) was added and the reaction was stirred at room temperature for 45 min. The solution was concentrated, diluted with water and acidified with HCl 2N. The precipitate obtained was filtered and washed with water to give the title compound (0.035g) as a white solid.
- 15

- ¹H-NMR (DMSO): 12.73 (bs,1H); 10.1 (s,1H); 8.27 (t,1H); 7.57 (d,2H); 7.17(d,2H); 7.11 (d,1H); 6.72-6.68 (m,3H); 4.18(d,2H);4.12(m,1H); 3.87(dd,1H); 3.06 (dd,1H);1.84 (s,3H)
- 20 I.R.(Nujol): 3422-3265cm⁻¹; 2725-2671cm⁻¹; 1730cm⁻¹; 1655cm⁻¹

Example 12

- 25 **(+/-)(E)-5,7-dichloro-4-[4(isobutyrylamino)phenylcarbomoylmethylene]-**
1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

- Intermediate 29 (0.040g) was suspended in EtOH /H₂O (1/1), then LiOH·H₂O (12mg) was added and the reaction was stirred at room temperature for 1.5 hours. The solution was concentrated, diluted with water and acidified with HCl 1N. The precipitate obtained was filtered and washed with water to give the title compound (0.030g) as a white solid.
- 30

- ¹H-NMR (DMSO): 12.72 (bs,1H); 10.11 (s,1H); 9.75 (s,1H); 7.53 (dd,2H); 7.09(s,1H); 6.70-6.66 (m,3H); 4.09 (bs,1H); 3.86 (m,1H); 3.06 (dd,1H); 2.54 (m,1H); 1.07 (d,6H)
- 35

I.R.(Nujol): 3298cm⁻¹; 1720cm⁻¹; 1661cm⁻¹
m.p. 230°C

Example 13

5 **(+/-)(E)-5,7-dichloro-4-**
[4(isobutylaminomethyl)phenyl]carbonylmethylene-1,2,3,4-
tetrahydro-quinoline-2-carboxylic acid

Intermediate 30 (0.89g) was suspended in EtOH /H₂O (2/1), then
10 LiOH·H₂O (26.4mg) was added and the reaction was stirred at room
temperature for 1 hour. The solution was acidified with HCl 2N and then
extracted with EA, the organic layer was washed with water, dried and the
solvent was removed under vacuum. The solid was suspended in EA then
15 petroleum ether was added and the solid was filtered to give the title
compound (0.06g) as a yellow solid.

¹H-NMR (DMSO): 12.71 (bs,1H); 10.11 (s,1H); 8.19 (t,1H); 7.66 (d,2H);
7.15 (d,1H); 7.11 (m,1H); 6.69 (d,1H); 6.68 (bs,1H); 6.67 (d,1H); 4.18
(d,2H); 4.11 (td,1H); 3.88(dd,1H); 3.85 (dd,1H); 2.39 (m,1H); 1.01 (d,6H)
20 I.R.(Nujol): 3302cm⁻¹; 1726cm⁻¹; 1653cm⁻¹;1628cm⁻¹

Example 14

25 **(+/-)(E)-5,7-dichloro-4-(4-morpholin-4-ylmethyl)-**
phenylcarbonylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic
acid

To a stirred solution of intermediate 31 (0.06g) in ethanol/water (6ml/2ml),
was added lithium hydroxide monohydrate (0.018g) and the reaction mixture
was stirred for 1 hrs. The solution was evaporated, then diluted with a
30 saturated solution of ammonium chloride (20ml) and extracted with ethyl
acetate (2x30ml), dried and concentrated in vacuum. The crude product was
trituated in dichloromethane/diethyl ether (1.5ml/3ml) to give the title
compound (0.04g).

¹H-NMR(DMSO): 11.0(bs, 1H), 7.65(d, 2H), 7.20(d, 2H), 6.80(bs, 1H), 6.73(d, 1H), 6.57(s, 1H), 6.54(d, 1H), 3.54(t, 4H), 3.38(s, 2H), 2.9(m, 1H), 2.31(m, 4H).

5 **Example 15**

(+/-)(E)-4-(4-carboxymethyl-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

Intermediate 32 (0.083g) was suspended in ethanol (12ml) and water (4ml).
10 To this solution LiOH.(H₂O) (0.039g) was added and the reaction mixture was stirred for 2 h 30 min at room temperature until a clear pale yellow solution was obtained. After evaporation of the solvent, HCl 1 N was then added dropwise until pH = 1 and the resulting acidic solution diluted with water (15ml); the precipitate thus formed was filtered, washed with small
15 amounts of cold water and crystallized from EA / CH (4 / 2) to give the title compound (0.053g) as a yellow solid.

¹H NMR (DMSO): 12.66 (s, 1H); 12.30 (s, 1H); 10.13 (s, 1H); 7.56 (d, 2H);
20 7.17 (d, 2H); 7.11 (d, 1H); 6.7-6.66 (m, 3H); 4.11 (m, 1H); 3.89 (dd, 1H); 3.49 (s, 2H); 3.04 (dd, 1H).

IR (nujol): 3368, 3180-3123, 1715, 1691.

m.p. >220°C

25

Example 16

(+/-)(E)-5,7-dichloro-4-(4-carbamoylmethyl-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

30

Intermediate 33 (0.150g) was dissolved in tetrahydrofuran (5ml), ethanol (20ml) and water (10ml). To this solution, LiOH(H₂O) (0.023g) was added and the reaction mixture was stirred for 15' at room temperature. HCl 2 N (5ml) was then added dropwise and the resulting acidic solution diluted with
35 water (30ml); the precipitate thus formed was filtered, washed with small

amounts of cold water and dried to give the title compound (0.041g) as a yellow solid.

5 ^1H NMR (DMSO): 12.70 (s, 1H); 10.10 (s, 1H); 7.55-7.39 (d+s, 3H); 7.17-7.10 (d, 3H); 6.83-6.67 (m, 4H); 4.11-3.90 (m, 2H); 3.28 (s, 2H); 3.05 (dd, 1H).

Example 17

10 (+/-)(E)-5,7-dichloro-4-[4-(2-isobutrylamino-ethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

15 Intermediate 34 (0.120g) was suspended in ethanol (20ml) and water (6ml). To this solution LiOH(H₂O) (0.017g) was added and the reaction mixture was stirred for 2 h at room temperature until a clear pale yellow solution was obtained. HCl 2 N (5ml) was then added dropwise and the resulting acidic solution diluted with water (30ml); the precipitate thus formed was filtered, washed with small amounts of cold water and dried to give the title compound (0.045g) as a yellow solid.

20 ^1H NMR (DMSO): 12.71 (s, 1H); 10.08 (s, 1H); 7.75 (t, 1H); 7.54 (d, 2H); 7.12 (d+s, 3H); 6.68 (m, 3H); 4.11 (m, 1H); 3.89 (dd, 1H); 3.21 (m, 2H); 3.04 (dd, 1H); 2.63 (t, 2H); 2.3 (m, 1H); 0.95 (d, 6H).

25 m. p.: 216-218 °C

Example 18

30 (+/-)(E)-5,7-dichloro-4-[4-(2-acetyl-amino-ethyl)phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

35 Intermediate 35 (0.100g) was suspended in ethanol (20ml) and water (7ml). To this solution, LiOH(H₂O) (0.033g) was added and the reaction mixture was stirred for 2 h at room temperature until a clear pale yellow solution was obtained. HCl 1 N (5ml) was then added dropwise and the resulting acidic

solution diluted with water (30ml); the precipitate thus formed was filtered, washed with small amounts of cold water and dried to give the title compound (0.054g) as a yellow solid.

5 ^1H NMR (DMSO): 12.71 (s, 1H); 10.13 (bs, 1H); 7.86 (t, 1H); 7.55 (d, 2H); 7.12 (d, 2H); 7.11 (bs, 2H); 6.98 (d, 1H); 6.70 (d, 1H); 6.70 (d, 1H); 6.67 (s, 1H); 4.1 (m, 1H); 3.9 (m, 1H); 3.2 (m, 1H); 3.09 (m, 1H); 1.76 (s, 3H).

m. p.: 254-256 °C

10

IR (nujol): 3395, 3339, 1653

Example 19

15 (+/-)(E)-5,7-dichloro-4-[4-(3-methyl-butyrylamino)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

20 To a stirred solution of intermediate 38 (0.043g) in ethanol/water (6ml/2ml), was added lithium hydroxide monohydrate (0.012g) and the reaction mixture was stirred for 1 1/2 hrs. The solution was evaporated, then diluted with a 3N solution of hydrochloric acid (5ml) and extracted with ethyl acetate (30ml). The organic layer was dried and concentrated in vacuum. The crude product was triturated in ethyl acetate/diethyl ether (1ml/5ml) to give the title compound (0.02g).

25

^1H -NMR(DMSO): 12.72(bs, 1H), 10.10(bs, 1H), 9.78(s, 1H), 7.55(d, 2H), 7.50(d, 2H), 7.10(d, 1H), 6.70(d, 1H), 6.67(s, 1H), 6.67(d, 1H), 4.10(m, 1H), 3.86(m, 1H), 3.07(m, 1H), 2.14(d, 2H), 2.05(m, 1H), 0.91(d, 6H).

30

Example 20

(+/-)(E)-4-(4-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid sodium salt

35 Example 5 (0.050g) was suspended in water (5ml). NaOH 1 M was then added (0.115ml) and the reaction mixture was stirred for 0.5 h at room

temperature until a clear pale yellow solution was obtained. The resulting solution was then freeze-dried for 48 h to give the title compound (0.027g) as a yellow solid.

5 ^1H NMR (DMSO): 11.21 (bs, 1H); 9.86 (bs, 1H); 7.64 (d, 2H); 7.47 (d, 2H); 6.74 (d, 1H); 6.68 (d, 1H); 6.52 (m, 1H); 6.50 (d, 1H); 3.49 (m, 1H); 3.34 (m, 1H); 2.60 (m, 1H); 2.00 (s, 3H).

IR (nujol): 3398, 2720, 1657, 1600.

10

Example 21

(+/-)-(E)-5,7-dibromo-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydroquinoline-2-carboxylic acid

15 Intermediate 43 (0.042g) was dissolved in 4/1 EtOH/H₂O (2ml) and to the stirred solution LiOH·H₂O (0.006g) was added. Stirring was continued at room temperature for 30min.. After concentration the solution 0.5ml, HCl (3N, 5ml) was added and the precipitate thus formed filtered, washed with small amounts of cold water and dried under vacuum to give the title compound (0.025g) as a pale yellow solid.

20

^1H -NMR (DMSO): 12.71 (1H, s); 10.15 (1H, s); 7.65 (2H, d); 7.30 (2H, t); 7.06 (1H, t); 6.95 (1H, s); 6.68 (1H, m); 4.11 (1H, t); 3.90 (1H, dd); 3.03 (1H, m).

25 I.R.: (nujol): 3362cm⁻¹, 3292cm⁻¹, 1720 cm⁻¹, 1597 cm⁻¹

m.p.: (°C): 115-120°C

Pharmacy Example

30	Intravenous Infusion	% w/v
	A glycine antagonist of formula (I)	0.3 - 0.5
	Polysorbate 80	1
	tris(hydroxymethyl)aminomethane	0.54
35	Dextrose solution 5% w/v	qs to volume

5 The glycine antagonist and Polysorbate were added to a solution of tris(hydroxymethyl)aminomethane in a 5% aqueous dextrose solution suitable for injection. The solution was filtered through a sterile 0.2 micron sterilising filter and filled in containers before being sterilised by autoclaving.

10 The affinity of a compound of the invention for strychnine insensitive glycine binding site located on the NMDA receptor complex was determined using the procedure of Kishimoto H. et al J. Neurochem 1981, 37, 1015-1024. The pKi values obtained with representative compounds of the invention are given in the following table.

Example No.	pKi
2	7.4
4	8.2
5	8.1
6	7.8
7	7.4
8	7.8
9	8.4
10	8.3
11	8.3
12	7.8
13	7.8
14	8.1
15	7.72
16	8.18
17	7.9
18	7.9
19	7.73
21	7.58

15 The ability of compounds of the invention to inhibit NMDA induced convulsions in the mouse was determined using the procedure of Chiamulera C et al. Psychopharmacology 1990, 102, 551-552. In this

test the ability of the compound when administered iv to inhibit the generalized seizures induced by an intracerebroventricular injection of NMDA in mice was examined at a number of dose levels.

- 5 From these results the dose required to protect 50% of the animals from the convulsive action of the NMDA was calculated. This expressed as mg/kg is referred to as the ED₅₀ value and results for representative compounds are given below:

Ex No.	ED ₅₀ mg/kg
2	0.2
4	1
5	0.2

10


No untoward effects have been observed when compounds of the invention have been administered to mice (either i.v. or po) at pharmacologically active doses.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of formula (I)



or a salt, or metabolically labile ester thereof wherein the exocyclic double-bond is in the trans (E) configuration;

R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO_2R_2 or COR_2 wherein R_2 represents hydroxy, methoxy, amino, alkylamino or dialkylamino; m is zero or an integer 1 or 2;

R_1 represents hydrogen, alkyl, alkoxy, nitro, trifluoromethyl, halogen or $(\text{CH}_2)_n\text{R}_3$ wherein

R_3 is a group selected from hydroxy, COR_4 , NR_5R_6 , NHCOR_7 or $\text{NHCONR}_8\text{R}_9$ group;

R_4 represents an alkoxy, amino or hydroxyl group;

R_5 and R_6 each independently represent hydrogen or alkyl group or

R_5 and R_6 together with the nitrogen atom to which they are attached represent a heterocyclic group;

R_7 represents a hydrogen atom or optionally substituted alkyl, alkoxy, aryl heterocyclic group;

R_8 represents hydrogen or alkyl group;

R_9 represents hydrogen, optionally substituted alkyl, aryl, heterocyclic or cycloalkyl group;

n is zero or an integer from 1 to 4.



2. A compound as claimed in claim 1 wherein m is 1 or 2, and R is a halogen atom in the 5 and/or 7 position.

3. A compound as claimed in claim 1 or claim 2 wherein m is 2 and R is chlorine in the 5 and 7 position.

5 4. A compound as claimed in any one of claims 1 to 3 wherein R_1 is hydrogen, chlorine, $(CH_2)_nCOR_4$ wherein R_4 is hydroxyl or amino, $(CH_2)_nNR_5R_6$ wherein R_5 and R_6 are each hydrogen or NR_5R_6 represents a morpholino group, $(CH_2)_nNHCOR_7$ wherein R_7 is hydrogen or C_{1-4} alkyl, $(CH_2)_nNHCONH_2$ and n is zero, 1 or 2.

10

5. A compound as claimed in claim 4 wherein R_1 represents hydrogen, chlorine, carboxymethyl, carbamoylmethyl, amino, morpholinomethyl, $(CH_2)_nNHCOR_7$ (wherein n is zero, 1 or 2 and R_7 is hydrogen, methyl isopropyl or isobutyl) or $CH_2NHCONH_2$.

15

6. (±) (E) 4-(4-acetylamino-phenylcarbamoylmethylene)-5,7-dichloro-1,2,3,4-tetrahydroquinoline-2-carboxylic acid and physiologically acceptable salts thereof.

20

7. A compound selected from

(±) (E) 5,7- Dichloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 7- Chloro-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

25

(±) (E) 5,7- Dibromo-4-phenylcarbamoylmethylene-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 4-(4-Amino-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

30

(±) (E) 4-(3-Acetylamino-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 5,7- Dichloro- 4-(4-isobutyrylamino-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 5,7- Dichloro- 4-[4-(3-methyl-butyrylamino)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid



(±) (E) 5,7- Dichloro- 4-(3-chloro-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 5,7- Dichloro- 4-[4-(isobutyrylamino-methyl)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

5 (±) (E) 5,7- Dichloro- 4-[4-(ureidomethyl)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 4-[4-(Acetylamino-methyl)-phenylcarbamoylmethylene]-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

10 (±) (E) 5,7- Dichloro- 4-(4-formylaminomethyl-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

(±) (E) 5,7- Dichloro- 4-(4-morpholin-4-ylmethyl-phenylcarbamoylmethylene)-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid

(±) (E) 4-[4-(2-Acetylamino-ethyl)-phenylcarbamoylmethylene]-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

15 (±) (E) 5,7- Dichloro- 4-[4-(2-isobutyrylamino-ethyl)-phenylcarbamoylmethylene]-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid


(±) (E) 4-(4-Carbamoylmethyl-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

20 (±) (E) 4-(4-Carboxymethyl-phenylcarbamoylmethylene)-5,7- dichloro-1,2,3,4-tetrahydro-quinoline-2-carboxylic acid,

and physiologically acceptable salts thereof.

8. A process for the preparation of compounds of claim 1 which comprises:

(a) cyclisation of a compound of formula (II)




(II)


wherein R and m are as defined in claim 1, R₁ is as defined in claim 1 or is a protected derivative thereof, R₁₀ is a carboxyl protecting group, R₁₁ represents bromine or iodine and R₁₂ represents H or a nitrogen protecting group,



(b) reacting an activated derivative of the carboxylic acid (III) wherein m , R , R_{10} and R_{12} are as defined for formula (II),




(III)



(IV)



with the amine of formula (IV) wherein R_1 is $(CH_2)_n NHCOR_7$ or $NCH_2NHCONR_8R_9$, and wherein n , R_7 , R_8 and R_9 are as defined in claim 1,

(c) reacting a compound of formula (V) for the preparation of a compound of formula (I)



(V)

wherein m , n , R , R_{10} and R_{12} are as defined above, with an activated derivative of the acid R_7CO_2H wherein R_7 is as defined in claim 1 or is a protected derivative thereof, or a compound of formula (VI) or (VII)



wherein R_8 and R_9 are as defined in claim 1 or are protected derivatives thereof and R_{13} is an optionally substituted phenoxy, halogen or an imidazole group, followed where necessary or desired by removal of any protecting group from the product of processes (a), (b) or (c).



9. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 7 in admixture with one or more physiologically acceptable carriers or excipients.

5 10. The use of a compound as claimed in any one of claims 1 to 7 in the manufacture of a medicament for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

10 11. Compounds as claimed in any one of claims 1 to 7 for use in therapy.

15 12. A method of treatment of a mammal including man for conditions where antagonising the effects of excitatory amino acids on the NMDA receptor complex is of therapeutic benefit comprising administration of an effective amount of a compound as claimed in any one of claims 1 to 7.

20 13. A compound as claimed in claim 1 wherein R_1 represents hydrogen, alkyl, alkoxy, nitro, trifluoromethyl, halogen or $(CH_2)_nR_3$ wherein R_3 is a group selected from hydroxy, COR_4 , NR_5R_6 , $NHCOR_7$, or $NHCONR_8R_9$ group;
 R_4 represents an alkoxy, or hydroxyl group;

25 R_5 and R_6 each independently represent hydrogen or alkyl group or R_5 and R_6 together with the nitrogen atom to which they are attached represent a heterocyclic group;

R_7 represents an optionally substituted alkyl, alkoxy, aryl or heterocyclic group;

R_8 represents hydrogen or alkyl group;

30 R_9 represents hydrogen, optionally substituted alkyl, aryl, heterocyclic or cycloalkyl group; n is zero or an interger from 1 to 4.

14. A compound as claimed in claim 13 wherein m is 2 and R is chlorine at the 5 and 7 position and R_1 represents hydrogen, $(CH_2)_nCOR_4$, $(CH_2)_nNR_5R_6$, $CH_2)_nNHCOR_7$ or $(CH_2)_nNHCONH_2$, n is zero, 1 or 2, R_4 represents hydroxyl, R_5 and R_6 each represent hydrogen or NR_5R_6 represents morpholino, R_7 represents C_{1-4} alkyl.

15. A compound of formula (I) substantially as hereinbefore described with reference to the Examples.

